US20230330154A1 - Methods of treating systemic graft- versus-host disease with extracellular vesicles - Google Patents
Methods of treating systemic graft- versus-host disease with extracellular vesicles Download PDFInfo
- Publication number
- US20230330154A1 US20230330154A1 US17/983,797 US202217983797A US2023330154A1 US 20230330154 A1 US20230330154 A1 US 20230330154A1 US 202217983797 A US202217983797 A US 202217983797A US 2023330154 A1 US2023330154 A1 US 2023330154A1
- Authority
- US
- United States
- Prior art keywords
- cells
- extracellular vesicles
- gvhd
- exosomes
- evs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 51
- 208000024908 graft versus host disease Diseases 0.000 title abstract description 99
- 208000009329 Graft vs Host Disease Diseases 0.000 title abstract description 95
- 230000009885 systemic effect Effects 0.000 title abstract description 28
- 210000004027 cell Anatomy 0.000 claims abstract description 60
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 37
- 239000002245 particle Substances 0.000 claims description 12
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 8
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 8
- 101000691214 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 50S ribosomal protein L44e Proteins 0.000 claims description 7
- 230000035755 proliferation Effects 0.000 claims description 7
- 230000001105 regulatory effect Effects 0.000 claims description 7
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 6
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 6
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 6
- 230000003213 activating effect Effects 0.000 claims description 5
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 claims description 3
- 102100034980 ICOS ligand Human genes 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 210000001808 exosome Anatomy 0.000 abstract description 112
- 210000001508 eye Anatomy 0.000 abstract description 21
- 210000003491 skin Anatomy 0.000 abstract description 18
- 230000001684 chronic effect Effects 0.000 abstract description 17
- 230000001154 acute effect Effects 0.000 abstract description 16
- 238000011282 treatment Methods 0.000 abstract description 16
- 210000004072 lung Anatomy 0.000 abstract description 15
- 238000001990 intravenous administration Methods 0.000 abstract description 14
- 210000004185 liver Anatomy 0.000 abstract description 13
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 12
- 210000004877 mucosa Anatomy 0.000 abstract description 10
- 210000000056 organ Anatomy 0.000 abstract description 10
- 238000007910 systemic administration Methods 0.000 abstract description 7
- 210000003195 fascia Anatomy 0.000 abstract description 5
- 210000001503 joint Anatomy 0.000 abstract description 5
- 210000004392 genitalia Anatomy 0.000 abstract description 4
- 238000001802 infusion Methods 0.000 abstract description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 33
- 208000024891 symptom Diseases 0.000 description 21
- 230000000694 effects Effects 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 20
- 230000008859 change Effects 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 19
- 239000003636 conditioned culture medium Substances 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 13
- 206010061218 Inflammation Diseases 0.000 description 12
- 206010030113 Oedema Diseases 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 230000004054 inflammatory process Effects 0.000 description 12
- 239000012528 membrane Substances 0.000 description 12
- 230000006052 T cell proliferation Effects 0.000 description 11
- 210000000130 stem cell Anatomy 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 210000002175 goblet cell Anatomy 0.000 description 10
- 210000004379 membrane Anatomy 0.000 description 10
- 210000001185 bone marrow Anatomy 0.000 description 9
- 210000004443 dendritic cell Anatomy 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 238000010172 mouse model Methods 0.000 description 9
- 229920001223 polyethylene glycol Polymers 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 208000016261 weight loss Diseases 0.000 description 9
- 206010012735 Diarrhoea Diseases 0.000 description 8
- 210000001072 colon Anatomy 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 230000004580 weight loss Effects 0.000 description 8
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 7
- 239000002202 Polyethylene glycol Substances 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 230000017074 necrotic cell death Effects 0.000 description 7
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 230000000735 allogeneic effect Effects 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 230000000112 colonic effect Effects 0.000 description 6
- 210000005003 heart tissue Anatomy 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- -1 miR-27a Proteins 0.000 description 6
- 239000011148 porous material Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 102000016359 Fibronectins Human genes 0.000 description 5
- 108010067306 Fibronectins Proteins 0.000 description 5
- 108700011259 MicroRNAs Proteins 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000006727 cell loss Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 239000012467 final product Substances 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 230000008102 immune modulation Effects 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 102100025222 CD63 antigen Human genes 0.000 description 4
- 102100027221 CD81 antigen Human genes 0.000 description 4
- 206010013774 Dry eye Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010015943 Eye inflammation Diseases 0.000 description 4
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 4
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 4
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 4
- 206010067993 Mucosal necrosis Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 230000006044 T cell activation Effects 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 210000002798 bone marrow cell Anatomy 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 210000003068 cdc Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 206010009887 colitis Diseases 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 210000004907 gland Anatomy 0.000 description 4
- 230000002962 histologic effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- FVVLHONNBARESJ-NTOWJWGLSA-H magnesium;potassium;trisodium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;acetate;tetrachloride;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Mg+2].[Cl-].[Cl-].[Cl-].[Cl-].[K+].CC([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O FVVLHONNBARESJ-NTOWJWGLSA-H 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000002679 microRNA Substances 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000012679 serum free medium Substances 0.000 description 4
- 238000000528 statistical test Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 3
- 238000011725 BALB/c mouse Methods 0.000 description 3
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 206010068786 Overlap syndrome Diseases 0.000 description 3
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 208000024340 acute graft versus host disease Diseases 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 208000027503 bloody stool Diseases 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 208000017760 chronic graft versus host disease Diseases 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 210000003683 corneal stroma Anatomy 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 210000003560 epithelium corneal Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000035861 hematochezia Diseases 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000003118 histopathologic effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 230000000527 lymphocytic effect Effects 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 108091032320 miR-146 stem-loop Proteins 0.000 description 3
- 108091024530 miR-146a stem-loop Proteins 0.000 description 3
- 108091048308 miR-210 stem-loop Proteins 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 208000013220 shortness of breath Diseases 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000000153 supplemental effect Effects 0.000 description 3
- 238000005199 ultracentrifugation Methods 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 101100165655 Arabidopsis thaliana BRO1 gene Proteins 0.000 description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 2
- 101100082597 Homo sapiens PDCD6IP gene Proteins 0.000 description 2
- 108091070494 Homo sapiens miR-22 stem-loop Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000007547 Laminin Human genes 0.000 description 2
- 108010085895 Laminin Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 102100033344 Programmed cell death 6-interacting protein Human genes 0.000 description 2
- 206010037868 Rash maculo-papular Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 208000006111 contracture Diseases 0.000 description 2
- 238000009295 crossflow filtration Methods 0.000 description 2
- 201000009805 cryptogenic organizing pneumonia Diseases 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001085 differential centrifugation Methods 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000008378 epithelial damage Effects 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 206010016165 failure to thrive Diseases 0.000 description 2
- 238000005188 flotation Methods 0.000 description 2
- 238000001249 flow field-flow fractionation Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 201000011486 lichen planus Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 208000012965 maculopapular rash Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000004264 monolayer culture Methods 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000005241 right ventricle Anatomy 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000822 sequential centrifugation Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000004876 tela submucosa Anatomy 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- 102000004899 14-3-3 Proteins Human genes 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- 206010004173 Basophilia Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 102100027217 CD82 antigen Human genes 0.000 description 1
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 206010016228 Fasciitis Diseases 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 101000760079 Homo sapiens 14-3-3 protein epsilon Proteins 0.000 description 1
- 101000914469 Homo sapiens CD82 antigen Proteins 0.000 description 1
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000980823 Homo sapiens Leukocyte surface antigen CD53 Proteins 0.000 description 1
- 101001091538 Homo sapiens Pyruvate kinase PKM Proteins 0.000 description 1
- 101000611194 Homo sapiens Trinucleotide repeat-containing gene 6A protein Proteins 0.000 description 1
- 108091070521 Homo sapiens let-7a-1 stem-loop Proteins 0.000 description 1
- 108091070522 Homo sapiens let-7a-2 stem-loop Proteins 0.000 description 1
- 108091070513 Homo sapiens let-7a-3 stem-loop Proteins 0.000 description 1
- 108091068853 Homo sapiens miR-100 stem-loop Proteins 0.000 description 1
- 108091069006 Homo sapiens miR-125b-1 stem-loop Proteins 0.000 description 1
- 108091069087 Homo sapiens miR-125b-2 stem-loop Proteins 0.000 description 1
- 108091044796 Homo sapiens miR-1290 stem-loop Proteins 0.000 description 1
- 108091069022 Homo sapiens miR-130a stem-loop Proteins 0.000 description 1
- 108091079265 Homo sapiens miR-1915 stem-loop Proteins 0.000 description 1
- 108091067692 Homo sapiens miR-199a-1 stem-loop Proteins 0.000 description 1
- 108091067467 Homo sapiens miR-199a-2 stem-loop Proteins 0.000 description 1
- 108091067484 Homo sapiens miR-199b stem-loop Proteins 0.000 description 1
- 108091070493 Homo sapiens miR-21 stem-loop Proteins 0.000 description 1
- 108091067573 Homo sapiens miR-222 stem-loop Proteins 0.000 description 1
- 108091070373 Homo sapiens miR-24-1 stem-loop Proteins 0.000 description 1
- 108091070374 Homo sapiens miR-24-2 stem-loop Proteins 0.000 description 1
- 108091070371 Homo sapiens miR-25 stem-loop Proteins 0.000 description 1
- 108091069018 Homo sapiens miR-27b stem-loop Proteins 0.000 description 1
- 108091068837 Homo sapiens miR-29b-1 stem-loop Proteins 0.000 description 1
- 108091068845 Homo sapiens miR-29b-2 stem-loop Proteins 0.000 description 1
- 108091072689 Homo sapiens miR-320e stem-loop Proteins 0.000 description 1
- 108091067013 Homo sapiens miR-337 stem-loop Proteins 0.000 description 1
- 108091032109 Homo sapiens miR-423 stem-loop Proteins 0.000 description 1
- 108091055320 Homo sapiens miR-4516 stem-loop Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 102100024221 Leukocyte surface antigen CD53 Human genes 0.000 description 1
- 108091008065 MIR21 Proteins 0.000 description 1
- 108091007424 MIR27B Proteins 0.000 description 1
- 108091046841 MiR-150 Proteins 0.000 description 1
- 108091027766 Mir-143 Proteins 0.000 description 1
- 108091062170 Mir-22 Proteins 0.000 description 1
- 108091080995 Mir-9/mir-79 microRNA precursor family Proteins 0.000 description 1
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 1
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 1
- 206010061297 Mucosal erosion Diseases 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010031009 Oral pain Diseases 0.000 description 1
- 206010067472 Organising pneumonia Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 102100034911 Pyruvate kinase PKM Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 108700031126 Tetraspanins Proteins 0.000 description 1
- 102000043977 Tetraspanins Human genes 0.000 description 1
- 210000000068 Th17 cell Anatomy 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 101150014014 Traf6 gene Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102100040241 Trinucleotide repeat-containing gene 6A protein Human genes 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001008 atrial appendage Anatomy 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000003339 best practice Methods 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000003443 bladder cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 208000015322 bone marrow disease Diseases 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004323 caveolae Anatomy 0.000 description 1
- 210000000182 cd11c+cd123- dc Anatomy 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 210000002583 cell-derived microparticle Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- NJDNXYGOVLYJHP-UHFFFAOYSA-L disodium;2-(3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC([O-])=CC=C21 NJDNXYGOVLYJHP-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000001174 endocardium Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 102000010660 flotillin Human genes 0.000 description 1
- 108060000864 flotillin Proteins 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000003370 grooming effect Effects 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 210000003897 hepatic stem cell Anatomy 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 102000046949 human MSC Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002134 immunopathologic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000035992 intercellular communication Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000006662 intracellular pathway Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 108091070946 miR-128 stem-loop Proteins 0.000 description 1
- 108091060382 miR-140 stem-loop Proteins 0.000 description 1
- 108091030617 miR-140-1 stem-loop Proteins 0.000 description 1
- 108091023370 miR-140-2 stem-loop Proteins 0.000 description 1
- 108091027034 miR-148a stem-loop Proteins 0.000 description 1
- 108091047758 miR-185 stem-loop Proteins 0.000 description 1
- 108091050874 miR-19a stem-loop Proteins 0.000 description 1
- 108091086850 miR-19a-1 stem-loop Proteins 0.000 description 1
- 108091088468 miR-19a-2 stem-loop Proteins 0.000 description 1
- 108091037787 miR-19b stem-loop Proteins 0.000 description 1
- 108091062762 miR-21 stem-loop Proteins 0.000 description 1
- 108091041631 miR-21-1 stem-loop Proteins 0.000 description 1
- 108091044442 miR-21-2 stem-loop Proteins 0.000 description 1
- 108091061917 miR-221 stem-loop Proteins 0.000 description 1
- 108091035591 miR-23a stem-loop Proteins 0.000 description 1
- 108091092825 miR-24 stem-loop Proteins 0.000 description 1
- 108091032978 miR-24-3 stem-loop Proteins 0.000 description 1
- 108091064025 miR-24-4 stem-loop Proteins 0.000 description 1
- 108091070404 miR-27b stem-loop Proteins 0.000 description 1
- 108091059501 miR-320a stem-loop Proteins 0.000 description 1
- 108091088570 miR-320a-1 stem-loop Proteins 0.000 description 1
- 108091070041 miR-320a-2 stem-loop Proteins 0.000 description 1
- 108091065447 miR-320a-3 stem-loop Proteins 0.000 description 1
- 108091054114 miR-320a-4 stem-loop Proteins 0.000 description 1
- 108091071616 miR-376c stem-loop Proteins 0.000 description 1
- 108091047084 miR-9 stem-loop Proteins 0.000 description 1
- 108091034121 miR-92a stem-loop Proteins 0.000 description 1
- 108091028159 miR-92a-1 stem-loop Proteins 0.000 description 1
- 108091025616 miR-92a-2 stem-loop Proteins 0.000 description 1
- 108091049973 miR-92a-4 stem-loop Proteins 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 210000002487 multivesicular body Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 210000004991 placental stem cell Anatomy 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000009613 pulmonary function test Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 210000005245 right atrium Anatomy 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000021058 soft food Nutrition 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Definitions
- GVHD graft-versus-host disease
- GVHD hematopoietic stem cell transplant
- GVHD GVHD-specific donor T cells that are able to mount a specific immune response targeting host tissues. This event is potentiated by conditioning of the host prior to HSCT in order to suppress the immune system and ensure effective engraftment. Host tissue damage is mediated by cytotoxic T cells involving a variety of mechanisms, including direct cell contact and the production of soluble pro-inflammatory mediators.
- Thl7 cells have been shown to be sufficient for induction of GVHD, whereas in others their absence has been shown to exacerbate disease. See, e.g., Yi et al, “Absence of Donor Th1 7 Leads to Augmented Th1 Differentiation and Exacerbated Acute-Graft-Versus-Host Disease,” Blood, 112:2101-2110 (2008); Kappel et al, “IL-17 Contributes to CD4-Mediated Graft-Versus-Host Disease,” Blood, 113:945-952 (2009).
- exosomes and microvesicles are important modes of intercellular communication by serving as vehicles for transfer between cells of membrane and cytosolic proteins, lipids, and RNA. See, e.g., Graca Raposo and Willem Stoorvogel, “Extracellular Vesicles: Exosomes, Microvesicles, and Friends,” The Journal of Cell Biology, Vol. 200, No. 4, 373-383 (2013).
- WO 2014/028493 describes exosomes derived from cardiosphere-derived cells (CDCs) and their therapeutic utility for the repair or regeneration of damaged or diseased cells or tissue, e.g., damaged cardiac tissue.
- US 2012/0315252 describes CDCs, their derivation from cardiospheres, and their therapeutic utility for increasing the function of a damaged or diseased heart of a mammal.
- WO 2005/012510 describes cardiospheres, their derivation from human or animal cardiac tissue biopsy samples, and their therapeutic utility in cell transplantation and functional repair of the myocardium or other organs.
- the present invention is based on the surprising discovery by the present inventors that extracellular vesicles, in particular exosomes derived from cardiosphere-derived cells (CDCs), have immunomodulatory capabilities on T cells and are effective in treating systemic graft-versus-host disease (GVHD), as demonstrated for the first time in a relevant mouse model of systemic GVHD.
- GVHD systemic graft-versus-host disease
- the advantage of the method of the present invention as described herein is that it is a safe, systemically-administered biologic therapy that can improve both survival and end-organ damage (e.g., gastrointestinal tract and eyes) in GVHD by modulating the immune response and reducing inflammation and fibrosis. This causes reduction in end-organ morbidities such as ocular GVHD and weight loss attributable to poor nutrient absorption in the gastrointestinal tract, leading to inter alia improved survival and presumably enhanced quality of life.
- end-organ damage e.g., gastrointestinal tract and eyes
- systemic GVHD is used interchangeably with “GVHD”, and refers to acute or chronic GVHD requiring or amenable to treatment by systemic administration of extracellular vesicles, e.g. exosomes and/or microvesicles, derived from CDCs.
- the present invention provides a method of safely treating systemic GVHD in a subject in need thereof, the method comprising systemically administrating to the subject a therapeutically effective amount of extracellular vesicles, e.g., exosomes and/or microvesicles, derived from CDCs, wherein systemic GVHD is a syndrome involving multiple organs, most commonly the skin, mucosa, gastrointestinal tract, liver, and lungs, wherein cells originating from a donor (typically bone marrow, T-cell, and/or hematopoietic stem cell donor) recognize and mount a deleterious immune response against antigens found in the immunocompromised recipient.
- a donor typically bone marrow, T-cell, and/or hematopoietic stem cell donor
- systemic administration of a therapeutically effective amount of extracellular vesicles results in treatment of systemic GVHD with respect to at least one organ selected from the group consisting of the skin, mucosa, gastrointestinal tract, liver, and lungs.
- said administration of a therapeutically effective amount of extracellular vesicles results in treatment of systemic GVHD with respect to at least two organs selected from the group consisting of the skin, mucosa, gastrointestinal tract, liver, and lungs.
- systemic administration of a therapeutically effective amount of extracellular vesicles results in treatment of systemic GVHD with respect to at least one organ selected from the group consisting of the skin, mucosa, gastrointestinal tract, liver, lungs, joints and fascia, and genitalia.
- said administration of a therapeutically effective amount of extracellular vesicles results in treatment of systemic GVHD with respect to at least two organs selected from the group consisting of the skin, mucosa, gastrointestinal tract, liver, lungs, joints and fascia, and genitalia.
- systemic administration of a therapeutically effective amount of extracellular vesicles, e.g., exosomes and/or microvesicles, derived from CDCs results in treatment of systemic GVHD with respect to at least one organ selected from the group consisting of the skin, mucosa, gastrointestinal tract, liver, lungs, joints and fascia, and genitalia, and the eyes.
- systemic administration of a therapeutically effective amount of extracellular vesicles, e.g., exosomes and/or microvesicles, derived from CDCs results in treatment of systemic GVHD with respect to the eyes.
- a therapeutically effective amount of extracellular vesicles e.g., exosomes and/or microvesicles, derived from CDCs, is systemically administered one or more times after the subject has undergone HSCT.
- a therapeutically effective amount of extracellular vesicles is systemically administered to the subject less than, e.g., 1 hour post HSCT.
- a therapeutically effective amount of extracellular vesicles is systemically administered to the subject less than, e.g., 1-24 hours post HSCT.
- a therapeutically effective amount of extracellular vesicles is systemically administered to the subject less than, e.g., 24-48 hours post HSCT. In some embodiments, a therapeutically effective amount of extracellular vesicles is systemically administered to the subject, e.g., 1-2 weeks post HSCT. In some embodiments, a therapeutically effective amount of extracellular vesicles is systemically administered to the subject, e.g., 2-3 weeks after post HSCT. In some embodiments, a therapeutically effective amount of extracellular vesicles is systemically administered to the subject, e.g., 4-8 weeks post HSCT.
- a therapeutically effective amount of extracellular vesicles is systemically administered to the subject, e.g., 1, 2, 3, 4, 5, 6, 7, and/or 8 weeks after HSCT, one or more times, e.g., 7 days apart between successive administrations.
- said subject is a mammal, e.g., a human; said systemic administration is via, e.g., intra-vascular administration, intraventricular administration, intrathecal administration, or intraperitoneal administration, wherein said intra-vascular administration is, e.g., intravenous, intra-arterial, or intracoronary infusion or injection.
- said systemic administration is via, e.g., intra-vascular administration, intraventricular administration, intrathecal administration, or intraperitoneal administration, wherein said intra-vascular administration is, e.g., intravenous, intra-arterial, or intracoronary infusion or injection.
- said extracellular vesicles are exosomes, microvesicles, membrane particles, membrane vesicles, exosome-like vesicles, ectosomes, ectosome-like vesicles, exovesicles, epididimosomes, argosomes, promininosomes, prostasomes, dexosomes, texosomes, archeosomes, oncosomes, or the like.
- said extracellular vesicles are derived from CDCs cultured in serum-free medium (e.g., IMDM) and incubated at about 5% O2 for about 15 days, wherein said extracellular vesicles are obtained after filtering CDC condition medium containing extracellular vesicles through a 1000 kDa pore sized filter.
- serum-free medium e.g., IMDM
- said extracellular vesicles are derived from CDCs cultured in serum-containing or serum-free medium and incubated at 2-20% O2 for 1-15 days, wherein said extracellular vesicles are obtained after filtering CDC condition medium containing extracellular vesicles through a 3-1000 kDa (e.g., 10 kDa) pore sized filter.
- extracellular vesicles are obtained by precipitation with polyethylene glycol (e.g., 25% PEG).
- extracellular vesicles e.g., exosomes
- a crystalloid solution e.g., Plasmalyte, normal saline
- aqueous solution gel, ointment, cream, topical or implantable hydrogel
- powder sustained-release polymer (e.g., PLGA and PLA), polyethylene glycol (PEG)-containing solution, suspension, emulsion, as part of a drug delivery device, insert, patch, or the like.
- PEG polyethylene glycol
- prior to use extracellular vesicles, e.g., exosomes, are resuspended in an appropriate buffer, e.g., sterile PBS with or without human serum albumin.
- exosomes can be stored for future use, e.g., frozen at ⁇ 80° C.
- extracellular vesicles e.g., exosomes
- extracellular vesicles are prepared from cardiospheres or CDCs.
- extracellular vesicles are prepared from regenerative stem cells such as embryonic stem cells, pluripotent stem cells, multipotent stem cells, induced pluripotent stem cells, post-natal stem cells, adult stem cells, mesenchymal stem cells, hematopoietic stem cells, endothelial stem cells, epithelial stem cells, neural stem cells, cardiac stem cells including cardiac progenitor cells, bone marrow-derived stem cells, adipose-derived stem cells, hepatic stem cells, peripheral blood derived stem cells, cord blood-derived stem cells, placental stem cells, or the like.
- regenerative stem cells such as embryonic stem cells, pluripotent stem cells, multipotent stem cells, induced pluripotent stem cells, post-natal stem cells, adult stem cells, mesenchymal stem cells, hematopoietic stem cells, endothelial stem cells, epithelial stem cells, neural stem cells, cardiac stem cells including cardiac progenitor cells, bone marrow-derived stem
- extracellular vesicles e.g., exosomes
- a modification may, in some embodiments, comprise inducing expression of a specific cell-surface marker on the exosome, which results in specific interaction with a receptor on a desired target tissue.
- the native contents of the exosome are removed and replaced with, or supplemented with, desired exogenous proteins and/or nucleic acids.
- extracellular vesicles include one or more microRNAs selected from: miR-146a, miR-148a, miR-22, miR-24, miR-210, miR-150, miR-140-3p, miR-19a, miR-27b, miR-19b, miR-27a, miR-376c, miR-128, miR-320a, miR-143, miR-21, miR-130a, miR-9, miR-185, and miR-23a.
- extracellular vesicles, e.g., exosomes comprise miR-146a and miR-210.
- extracellular vesicles include one or more microRNAs selected from: hsa-miR-23 ⁇ -3p, hsa-miR-130a-3p, hsa-miR-21-5p, hsa-miR-4516, hsa-let-7a-5p, hsa-miR-125b-5p, hsa-miR-199a-3p, hsa-miR-199b-3p, hsa-miR-22-3p, hsa-miR-24-3p, hsa-miR-1290, hsa-miR-320e, hsa-miR-423-5p, hsa-miR-22-3p, hsa-miR-222-3p (also known as miR-221-3p), hsa-miR-100-5p, hsa-miR-3
- extracellular vesicles e.g., exosomes
- biological proteins e.g., transcription factors, cytokines, growth factors, and similar proteins capable of modulating signaling pathways in a target cell.
- the biological protein is capable of facilitating regeneration and/or improved function of a tissue.
- the biological protein is capable of modulating pathways related to Irak1, Traf6, toll-like receptor (TLR) signaling pathway, NOX-4, SMAD-4, and/or TGF- ⁇ .
- the biological protein is related to exosome formation and packaging of cytosolic proteins such as Hsp70, Hsp90, 14-3-3 epsilon, PKM2, GW182 and AG02.
- extracellular vesicles, e.g., exosomes contain signaling lipids, e.g., ceramide and derivatives.
- extracellular vesicles e.g., exosomes
- extracellular vesicles express tetraspanins, e.g., CD63, CD81, CD82, CD53, and/or CD37.
- extracellular vesicles, e.g., exosomes express one or more lipid raft associated proteins (e.g., glycosylphosphatidylinositol-anchored proteins and flotillin), cholesterol, sphingomyelin, and/or hexosylceramides.
- lipid raft associated proteins e.g., glycosylphosphatidylinositol-anchored proteins and flotillin
- cholesterol e.g., sphingomyelin
- hexosylceramides e.g., hexosylceramides.
- extracellular vesicles e.g., exosomes
- extracellular vesicles have a diameter of, e.g., about 15-250 nm, about 15-205 nm, about 90-220 nm, about 30-200 nm, about 20-150 nm, about 70-150 nm, or about 40-100 nm.
- extracellular vesicles e.g., microvesicles, have a diameter of, e.g., about 100-1000 nm.
- extracellular vesicles e.g., exosomes
- extracellular vesicles are purified such that contaminants or undesired compounds are removed from the exosomes.
- the patient is administered substantially purified exosomes such that about 50% to 90%, or up to 100%), of the contaminants are removed from the exosomes.
- an exosome preparation is essentially free of non-exosome components.
- extracellular vesicles e.g., exosomes
- extracellular vesicles are administered in combination with one or more additional agents.
- the exosomes are administered in combination with one or more proteins or nucleic acids derived from the exosome.
- the cells from which the exosomes are isolated are administered in conjunction with the exosomes.
- such an approach advantageously provides an acute and more prolonged duration of exosome delivery (e.g., acute based on the actual exosome delivery and prolonged based on the cellular delivery, the cells continuing to secrete exosomes post-delivery).
- the dose of extracellular vesicles ranges about 1.0 ⁇ 10 5 to about 1.0 ⁇ 10 10 exosomes.
- the exosome dose is administered on a per kilogram basis, e.g., about 1.0 ⁇ 10 5 exosomes/kg to about 1.0 ⁇ 10 9 exosomes/kg.
- exosomes are delivered in an amount based on the mass of the target tissue, e.g., about 1.0 ⁇ 10 5 exosomes/gram of target tissue to about 1.0 ⁇ 10 9 exosomes/gram of target tissue.
- exosomes are administered based on a ratio of the number of exosomes to the number of cells in a particular target tissue. If exosomes are to be administered in conjunction with the concurrent therapy (e.g., cells that can still shed exosomes, pharmaceutical therapy, nucleic acid therapy, and the like) the dose of exosomes administered can be adjusted accordingly (e.g., increased or decreased as needed to achieve the desired therapeutic effect).
- concurrent therapy e.g., cells that can still shed exosomes, pharmaceutical therapy, nucleic acid therapy, and the like
- the dose of exosomes administered can be adjusted accordingly (e.g., increased or decreased as needed to achieve the desired therapeutic effect).
- the present invention further provides a formulation comprising extracellular vesicles for use in the treatment of systemic GVHD according to the aforementioned method.
- the present invention further provides a use of the aforementioned formulation for treating systemic GVHD according to the aforementioned method.
- FIG. 1 is a diagram showing how systemic GVHD is induced in BALB/c mice.
- FIG. 2 A is a photograph showing an example of Grade 0 for the posture criterion of the GVHD score.
- FIG. 2 B is a photograph showing an example of Grade 1 for the posture criterion of the GVHD score.
- FIG. 2 C is a photograph showing an example of Grade 2 for the posture criterion of the GVHD score.
- FIG. 3 A is a photograph showing an example of Grade 0 for the fur texture criterion of the GVHD score.
- FIG. 3 B is a photograph showing an example of Grade 1 for the fur texture criterion of the GVHD score.
- FIG. 3 C is a photograph showing an example of Grade 2 for the fur texture criterion of the GVHD score.
- FIG. 4 A is a photograph showing an example of Grade 0 for the skin integrity criterion of the GVHD score.
- FIG. 4 B is a photograph showing an example of Grade 1 for the skin integrity criterion of the GVHD score.
- FIG. 4 C is a photograph showing an example of Grade 2 for the skin integrity criterion of the GVHD score.
- FIG. 5 schematically illustrates the study design for evaluating the efficacy of extracellular vesicles to treat systemic GVHD.
- FIG. 6 A graphically shows the effects of intravenous administration of extracellular vesicles on the weight of the mouse model of systemic GVHD.
- FIG. 6 B shows the same data of FIG. 6 A as AUC to enable effective comparison of groups by statistical test.
- FIG. 7 A graphically shows the effects of intravenous administration of extracellular vesicles on the overall GVHD score.
- FIG. 7 B shows the same data of FIG. 7 A as AUC to enable effective comparison of groups by statistical test.
- FIG. 8 A graphically shows the effects of intravenous administration of extracellular vesicles on the posture criterion of the GVHD score.
- FIG. 8 B graphically shows the effects of intravenous administration of extracellular vesicles on the activity criterion of the GVHD score.
- FIG. 8 C graphically shows the effects of intravenous administration of extracellular vesicles on the fur activity criterion of the GVHD score.
- FIG. 8 D graphically shows the effects of intravenous administration of extracellular vesicles on the skin integrity criterion of the GVHD score.
- FIG. 9 graphically shows the effects of intravenous administration of extracellular vesicles on the survival of the mouse model of systemic GVHD.
- FIGS. 10 A-B graphically show the effects of intravenous administration of extracellular vesicles on the diarrhea incidence of the mouse model of systemic GVHD.
- FIGS. 11 A-C graphically show the effects of intravenous administration of extracellular vesicles on the eye inflammation of the mouse model of systemic GVHD.
- FIG. 12 graphically shows the effects of intravenous administration of extracellular vesicles on the colitis scores of the mouse model of systemic GVHD.
- FIG. 13 graphically shows the same data as in FIG. 12 as sum colitis scores.
- FIG. 14 graphically shows the effects of intravenous administration of extracellular vesicles on the colon histopathology severity scores of the mouse model of systemic GVHD.
- FIG. 15 graphically shows the effects of intravenous administration of extracellular vesicles on the eye average histopathology scores of the mouse model of systemic GVHD.
- FIG. 16 is a western blot showing CDC-EVs' contents of recognized exosomes markers.
- FIG. 17 graphically shows the expression of immune molecules involved in T and natural killer (NK) immune response on CDC-EVs.
- FIG. 18 Shows in vitro update of CDC-EVs in Jurkat T cells.
- FIG. 19 shows the immune modulation of PHA-induced T cells proliferation by and CDC-EVs.
- FIG. 20 graphically shows the down-regulation of PHA-induced CD69 and/or HLA-DR expression by CDCs and CDC-EVs.
- FIG. 21 graphically shows that CDC-EVs down regulate PHA-induced T cells
- FIG. 22 graphically shows that immune modulation of PHA-induced CD4+ and CD8+ T cells proliferation by CDC-EVs.
- GVHD has been classically divided into acute and chronic variants based upon the time of onset using a cutoff of 100 days.
- Clinical manifestations of chronic GVHD include skin involvement resembling lichen planus or the cutaneous manifestations of scleroderma, dry oral mucosa with ulcerations and sclerosis of the gastrointestinal tract, and a rising serum bilirubin concentration.
- patients with acute GVHD commonly demonstrate a classic maculopapular rash, abdominal cramps with diarrhea, and a rising serum bilirubin concentration.
- this conventional division has been challenged by the recognition that signs of acute and chronic GVHD may occur outside of these designated periods.
- NIH consensus criteria for identifying signs and symptoms of chronic GVHD are summarized in Table 1. See, e.g., Jagasia et al., “National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report,” Biol Blood Marrow Transplant, 21:389 (2015).
- Chronic GVHD Patients diagnosed with chronic GVHD are then subclassified based upon the presence or absence of features of acute GVHD into one of two categories: (i) classic chronic GV.HD: Features of chronic GVH-D are present without signs or symptoms of acute GVH-D; (ii) overlap syndrome: Features of both chronic GVHD and acute GVHD are present.
- GVHD seen in the overlap syndrome include changes in the skin (skin erythema, maculopapular rash, pruritus), mouth (gingivitis, mucositis, oral erythema, oral pain), gastrointestinal symptoms (anorexia, nausea, vomiting, diarrhea, weight loss, failure to thrive), liver dysfunction (elevations in bilirubin, alkaline phosphatase, ALT, or AST), and organizing pneumonia (also called bronchiolitis obliterans organizing pneumonia).
- terms such as “treating” and “treatment” as used herein refer to therapeutic measures that cure, slow down, lessen symptoms of, and/or halt progression of a diagnosed pathologic condition or disorder.
- a subject is successfully “treated” according to the methods of the present invention if the subject shows clinical improvement according to the NIH consensus criteria for identifying signs and symptoms of chronic GVHD.
- Cardiospheres are undifferentiated cardiac cells that grow as self-adherent clusters as described in WO 2005/012510, and Messina et al, “Isolation and Expansion of Adult Cardiac Stem Cells From Human and Murine Heart,” Circulation Research, 95: 911-921 (2004), the disclosures of which are herein incorporated by reference in their entirety.
- heart tissue can be collected from a patient during surgery or cardiac biopsy.
- the heart tissue can be harvested from the left ventricle, right ventricle, septum, left atrium, right atrium, crista terminalis, right ventricular endocardium, septal or ventricle wall, atrial appendages, or combinations thereof.
- a biopsy can be obtained, e.g., by using a percutaneous bioptome as described in, e.g., U.S. Patent Application Publication Nos. 2009/012422 and 2012/0039857, the disclosures of which are herein incorporated by reference in their entirety.
- the tissue can then be cultured directly, or alternatively, the heart tissue can be frozen, thawed, and then cultured.
- the tissue can be digested with protease enzymes such as collagenase, trypsin and the like.
- the heart tissue can be cultured as an explant such that cells including fibroblast-like cells and cardiosphere-forming cells grow out from the explant.
- an explant is cultured on a culture vessel coated with one or more components of the extracellular matrix (e.g., fibronectin, laminin, collagen, elastin, or other extracellular matrix proteins).
- the tissue explant can be cultured for about 1, 2, 3, 4, or more weeks prior to collecting the cardiosphere-forming cells.
- a layer of fibroblast-like cells can grow from the explant onto which cardiosphere-forming cells appear.
- Cardiosphere-forming cells can appear as small, round, phase-bright cells under phase contrast microscopy.
- Cells surrounding the explant including cardiosphere-forming cells can be collected by manual methods or by enzymatic digestion.
- the collected cardiosphere-forming cells can be cultured under conditions to promote the formation of cardiospheres.
- the cells are cultured in cardiosphere-growth medium comprising buffered media, amino acids, nutrients, serum or serum replacement, growth factors including but not limited to EGF and bFGF, cytokines including but not limited to cardiotrophin, and other cardiosphere promoting factors such as but not limited to thrombin.
- Cardiosphere-forming cells can be plated at an appropriate density necessary for cardiosphere formation, such as about 20,000-100,000 cells/mL.
- the cells can be cultured on sterile dishes coated with poly-D-lysine, or other natural or synthetic molecules that hinder the cells from attaching to the surface of the dish. Cardiospheres can appear spontaneously about 2-7 days or more after cardiosphere-forming cells are plated.
- CDCs are a population of cells generated by manipulating cardiospheres in the manner as described in, e.g., U.S. Patent Application Publication No. 2012/0315252, the disclosures of which are herein incorporated by reference in their entirety.
- CDCs can be generated by plating cardiospheres on a solid surface which is coated with a substance which encourages adherence of cells to a solid surface of a culture vessel, e.g., fibronectin, a hydrogel, a polymer, laminin, serum, collagen, gelatin, or poly-D-lysine, and expanding same as an adherent monolayer culture.
- CDCs can be repeatedly passaged, e.g., passaged two times or more, according to standard cell culturing methods.
- Exosomes are vesicles formed via a specific intracellular pathway involving multivesicular bodies or endosomal-related regions of the plasma membrane of a cell. Exosomes can range in size from approximately 20-150 nm in diameter. In some cases, they have a characteristic buoyant density of approximately 1.1-1.2 g/mL, and a characteristic lipid composition. Their lipid membrane is typically rich in cholesterol and contains sphingomyelin, ceramide, lipid rafts and exposed phosphatidylserine. Exosomes express certain marker proteins, such as integrins and cell adhesion molecules, but generally lack markers of lysosomes, mitochondria, or caveolae.
- the exosomes contain cell-derived components, such as but not limited to, proteins, DNA and RNA (e.g., microRNA and noncoding RNA).
- exosomes can be obtained from cells obtained from a source that is allogeneic, autologous, xenogeneic, or syngeneic with respect to the recipient of the exosomes.
- miRNAs function as post-transcriptional regulators, often through binding to complementary sequences on target messenger RNA transcripts (mRNAs), thereby resulting in translational repression, target mRNA degradation and/or gene silencing.
- miR146a exhibits over a 250-fold increased expression in CDCs, and miR210 is upregulated approximately 30-fold, as compared to the exosomes isolated from normal human dermal fibroblasts.
- Exosomes derived from cardiospheres and CDCs are described in, e.g., WO 2014/028493, the disclosures of which are herein incorporated by reference in their entirety.
- Methods for preparing exosomes can include the steps of: culturing cardiospheres or CDCs in conditioned media, isolating the cells from the conditioned media, purifying the exosome by, e.g., sequential centrifugation, and optionally, clarifying the exosomes on a density gradient, e.g., sucrose density gradient.
- the isolated and purified exosomes are essentially free of non-exosome components, such as components of cardiospheres or CDCs.
- Exosomes can be resuspended in a buffer such as a sterile PBS buffer containing 0.01-1% human serum albumin. The exosomes may be frozen and stored for future use.
- Exosomes can be prepared using a commercial kit such as, but not limited to the ExoSpinTM Exosome Purification Kit, Invitrogen® Total Exosome Purification Kit, PureExo® Exosome Isolation Kit, and ExoCapTM Exosome Isolation kit. Methods for isolating exosome from stem cells are found in, e.g., Tan et al, Journal of Extracellular Vesicles, 2:22614 (2013); Ono et al., Sci Signal, 7(332):ra63 (2014) and U.S. Application Publication Nos. 2012/0093885 and 2014/0004601.
- differential ultracentrifugation has become a leading technique wherein secreted exosomes are isolated from the supernatants of cultured cells.
- This approach allows for separation of exosomes from nonmembranous particles, by exploiting their relatively low buoyant density. Size exclusion allows for their separation from biochemically similar, but biophysically different microvesicles, which possess larger diameters of up to 1,000 nm.
- exosome sizes will possess a diameter ranging from 30-200 nm, including sizes of 40-100 nm. Further purification may rely on specific properties of the particular exosomes of interest. This includes, e.g., use of immunoadsorption with a protein of interest to select specific vesicles with exoplasmic or outward orientations.
- differential centrifugation is the most commonly used for exosome isolation.
- This technique utilizes increasing centrifugal force from 2000 ⁇ g to 10,000 ⁇ g to separate the medium- and larger-sized particles and cell debris from the exosome pellet at 100,000 ⁇ g. Centrifugation alone allows for significant separation/collection of exosomes from a conditioned medium, although it is insufficient to remove various protein aggregates, genetic materials, particulates from media and cell debris that are common contaminants.
- Enhanced specificity of exosome purification may deploy sequential centrifugation in combination with ultrafiltration, or equilibrium density gradient centrifugation in a sucrose density gradient, to provide for the greater purity of the exosome preparation (flotation density 1. 1-1.2 g/mL) or application of a discrete sugar cushion in preparation.
- ultrafiltration can be used to purify exosomes without compromising their biological activity.
- MWCO molecular weight cutoff
- THF tangential flow filtration
- HPLC can also be used to purify exosomes to homogeneously sized particles and preserve their biological activity as the preparation is maintained at a physiological pH and salt concentration.
- F1FFF Flow field-flow fractionation
- exosomes may be isolated from specific exosomes of interest. This includes relying on antibody immunoaffinity to recognizing certain exosome-associated antigens. As described, exosomes further express the extracellular domain of membrane-bound receptors at the surface of the membrane. This presents a ripe opportunity for isolating and segregating exosomes in connections with their parental cellular origin, based on a shared antigenic profile. Conjugation to magnetic beads, chromatography matrices, plates or microfluidic devices allows isolating of specific exosome populations of interest as may be related to their production from a parent cell of interest or associated cellular regulatory state. Other affinity-capture methods use lectins which bind to specific saccharide residues on the exosome surface.
- heart biopsies were minced into small fragments and briefly digested with collagenase. Explants were then cultured on 20 mg/mL fibronectin-coated dishes. Stromal-like flat cells and phase-bright round cells grew out spontaneously from tissue fragments and reached confluency by 2-3 weeks. These cells were harvested using 0.25% trypsin and were cultured in suspension on 20 mg/mL poly-d-lysine to form self-aggregating cardiospheres. CDCs were obtained by plating and expanding the cardiospheres on a fibronectin-coated flask as an adherent monolayer culture.
- CDCs When the CDCs reached the desired confluency, the flask was washed three times with PBS. CDCs were treated with serum-free medium (IMDM) and were incubated at 37° C. at 5% 02, 5% C02 for 15 days. After 15 days, the conditioned medium was collected in 225 mL BD Falcon polypropylene conical tubes (BD 352075—Blue Top) and centrifuged at 2,000 rpm for 20 minutes at 4° C. to remove cells and debris (care was taken not to disturb the pellet). The conditioned medium was run through a 0.45 ⁇ membrane filter. The conditioned medium was concentrated using centrifugal filter.
- IMDM serum-free medium
- a 3 KDa Centricon Plus-70 Centrifugal Filter was pre-rinsed with 10-25 mL of molecular grade water and was centrifuged at 3220 g for five minutes at 18° C. Once the filter was rinsed, all remaining water was carefully removed without touching the filter. 15 mL of the conditioned medium was added to the filter and was centrifuged at 3220 g for 45 minutes at 18° C. After the initial spin, the remaining medium was mixed by pipetting and then spun again until the desired concentration was reached. The final sample was then run through a 0.22 ⁇ m syringe filter. 25 ⁇ L of the concentrated conditioned medium was diluted in 975 ⁇ L of PBS for particle count using the Nanosight.
- the appropriate volume of 25% PEG was added to the filtered concentrated conditioned medium.
- the samples were incubated at 4° C. for 12-16 hours on an orbital shaker. Once incubation was complete, the samples were centrifuged at 1500 g for 30 minutes at 4° C. The supernatant was carefully removed without disrupting the pellet. The pellet was resuspended in the desired volume of serum-free medium and sampled for particle count.
- CDC-EV (10 KDa or 1000 KDa) drug substance is obtained after filtering CDC conditioned medium (CM) containing EVs through a 10 KDa or 1000 KDa pore size filter.
- CM CDC conditioned medium
- the final product, composed of secreted EVs and concentrated CM, is formulated in PlasmaLyte A and stored frozen.
- Extracellular vesicles originating from human bone marrow mesenchymal stem cells are obtained after filtering MSC CM containing EVs through a 10 KDa pore size filter following a similar process as for CDC-EV production.
- MSC-EVs are a non-cellular, filter sterilized product obtained from human MSCs cultured under defined, serum-free conditions.
- the final product, composed of secreted EVs and concentrated CM, is formulated in PlasmaLyte A and stored frozen. The frozen final product is “ready to use” for direct subconjunctival injection after thawing.
- Extracellular vesicles originating from newt Al cell line are obtained after filtering Al cell line CM containing EVs through a 10 KDa pore size filter following a similar process as for CDC-EV production.
- Newt-EVs are a non-cellular, filter sterilized product obtained from newt Al cells cultured under defined, serum-free conditions.
- the final product, composed of secreted EVs and concentrated CM, is formulated in PlasmaLyte A and stored frozen. The frozen final product is ready to use for direct subconjunctival injection after thawing.
- test article is a non-cellular, filter sterilized product obtained from human CDCs cultured under defined, serum-free conditions, prepared as exemplified in Examples 1-4.
- the general characteristics of the test article are summarized in Table 2.
- test and control articles were thawed for dosing overnight or on the day of dosing, and kept on wet ice throughout the dosing procedures.
- Example 6 Systemic GVHD Animal Model; Study Design; Assessment of GVHD
- FIGS. 1 and 5 illustrate how the animal model of systemic GVHD was generated, based on, e.g., Schroeder and DiPersio, “Mouse Models of Graft-Versus-Host Disease: Advances and Limitations,” Disease Models & Mechanisms, 4:318-333 (2011); van Leeuwen et al, “A Two-Phase Pathogenesis of Graft-Versus-Host Disease in Mice,” Bone Marrow Transplantation, 29: 151-158 (2002), with a few modifications.
- TBI total body irradiation
- the BALB/c recipients were given an intravenous injection, using a syringe with 30-gauge needle into the tail vein, of a combination of 2 ⁇ 10 6 splenocytes and T-cell depleted (CD3 ⁇ ) bone marrow cells 5 ⁇ 10 6 in sterile 1 ⁇ PBS.
- Bone marrow (BM) and splenic cells (SC) were obtained from donor male C57BL/6 mice.
- the bone marrow cells were isolated using standard flushing practices and T-cell depleted using the cell surface T-cell antigen CD3, with a CD3-biotin kit from Miltenyi Biotec (130-093-021).
- Recipient animals were randomized into 3 groups of 15 animals each.
- FIGS. 8 A-D As assessed using the multi-parameter GVHD scoring systems shown in Table 4 and as shown in FIG. 7 A , intravenous injection of splenocytes and bone marrow cells induced GVHD in all animals. As shown in FIG. 7 A , decreases in the overall GVHD score were observed in both groups dosed with CDC-EVs, and individual GVHD parameters (posture, activity, fur texture, skin integrity) are summarized in FIGS. 8 A-D .
- the AUC was calculated to enable effective comparison of the groups by statistical test.
- the AUC was calculated to enable effective comparison of the groups by statistical test.
- eye inflammation was assessed and scored, wherein a drop of 1% sodium fluorescein was applied to each eye, then the eye was rinsed off with saline, and viewed the fluorescence of the cornea with cobalt blue light under magnification.
- FIGS. 11 A-C show that while there was a trend toward lower eye score (therefore less corneal staining, a sign that there is reduced eye inflammation) in the CDC-EV-treated groups, with the high dose-treated animals performing even better.
- GVHD colitis in mice included primarily mononuclear inflammation in the colonic mucosa; expansion of the submucosa and lymphatic vessels by edema; epithelial damage or mucosal necrosis, with or without erosion and infiltration of neutrophils; and depletion of goblet cells. See, e.g., Eigenbrodt et al, “Histologic Similarity of Murine Colonic Graft-versus-host Disease (GVHD) to Human Colonic GVHD and Inflammatory Bowel Disease,” Am J Pathol, 137: 1065-76 (1990).
- lymphocytic satellitosis the infiltration of lymphocytes into the colonic gland with epithelial cell apoptosis
- epithelial hyperplasia characterized by gland elongation, basophilia and increased mitotic figures
- mesenteric adipose necrosis with subacute inflammation the infiltration of neutrophils, macrophages and fewer lymphocytes and plasma cells into the mesentery adjacent the colon.
- lymphocytic satellitosis characterized by infiltration of low numbers of lymphocytes into the corneal epithelium, with concurrent epithelial cell vacuolization and/or apoptosis; corneal epithelial necrosis with progression to ulceration was present in one sample. See, e.g., Perez et al, “Limbus Damage in Ocular Graft-versus-Host-Disease,” Biol Blood Marrow Transplant, 17: 270-273 (2011).
- Corneal subacute inflammation was characterized by infiltration of neutrophils, lymphocytes or histiocytes into the corneal stroma and/or epithelium, accompanied by stromal edema or occasional foci of stromal necrosis.
- Neovascularization was characterized by ingrowth of blood vessels into the corneal stroma.
- Subacute inflammation was also observed in the limbus, conjunctiva (when present) and the anterior uveal tract, including the iris or anterior chamber.
- Mineralization was visible in the corneal stroma or in the immediate sub-basilar zone of the corneal epithelium (subepithelial).
- Lens fiber degeneration (cataract formation), characterized by posterior migration and disorganization of the lens epithelium and bladder cell formation, was observed as well.
- lymphocytic satellitosis, corneal and anterior uveal subacute inflammation and neovascularization scores were most severe in Group 1 (untreated); with lower scores or complete absence of these lesions in the test article-treated animals (Groups 2 and 3).
- CDC-EVs For FIG. 16 , the expression of exosome informative markers was analyzed by CDC-EVs using Western blotting.
- CDCs and dendritic cells (DC) lysates as well as exosome-free supernatant (SN) were used as controls.
- CDC-EVs expressed expected exosome markers CD81, CD63 and ALIX while SN was completely negative.
- CDC-EVs were next analyzed for the surface expression of immune relevant markers.
- CDC-EVs/beads were treated successively with 100 mM glycine and 2% BSA buffers in order to block any eventual non-specific binding of these EVs eads with antibodies or with beads.
- EVs/beads were stained with specific antibodies against relevant immune molecules acquired on Canto II BD Facs and analyzed by FlowJo software. Beads incubated with the same amount of respective antibodies were used as a control.
- CDC-EVs Compared to beads-antibody control, CDC-EVs expressed HLA class I molecules and CD86, but were negative for HLA II and CD80 molecules. CDC-EVs seem to express the co-stimulatory PD-L1 molecule but not the ICOS-L. NK activating receptor ligands were remarkably expressed on the CDC-EVs. For FIG. 17 , significant expression of both EVs markers CD81 and CD63 was detected.
- Monocytes were isolated from blood samples obtained from two different healthy donors. Isolated-monocytes were then stimulated for 6 days with a combination of GM-CSF (20 ng/ml) and IL4 (20 ng/ml) to allow their differentiation to DC. Differentiation of monocytes with GM-CSF+IL4 generates immature DC (iDC) marked by moderate expression of HLA II, CD80, and CD86 molecules, absence of CD 16 (marker of monocytes/macrophages), and low expression of TLR-2. These monocyte-derived iDC were then incubated for an overnight with HLA-mismatched CDC-EVs.
- GM-CSF 20 ng/ml
- IL4 20 ng/ml
- iDC cultured with EVs displayed features of mature DC (mDC); they up-regulated their HLA II, CD80 and CD86 molecules, which is recognized as mDC properties, as shown in FIG. 28 .
- iDC-EVs 1 ⁇ 10 4 of iDCs or iDCs that were in contact with EVs (iDC-EVs) were co-cultured with autologous T cells (1 ⁇ 10 5 ) in U-bottom 96 wells plates for another 6 days.
- Autologous T cells co-cultured with iDC or iDC-EVs where analyzed for their expression of CD69 and HLA-DR, and for their proliferation.
- CDC-EVs The capacity of CDC-EVs to stimulate T cells when presented by mature DC (mDC) was evaluated. Given that mDC have very low phagocytic activity and to insure appropriate uptake of EVs and based on previous experience of phagocytizing apoptotic bodies, the maturation of DC was induced by treating iDC and iDC-EVs for an overnight with IFN ⁇ (500 IU/ml), which is a recognized inducer of DC maturation. Compared to iDC, these mDC showed higher expression of HLA II, CD80 and CD86, and higher expression of TLR-2, which are the know features of mDC. The presence of CDC-EVs during iDC maturation to mDC further up-regulated HLA II, CD86, CD80, and TLR-2 molecules, as shown in FIG. 30 .
- mDC or mDC-EVs were then co-cultured with autologous T cells (1 ⁇ 10 5 ) in U-bottom 96-wells plates or 6 days and their activation (expression of CD69 and HLA-DR) and proliferation was analyzed.
- T cells for CDC-EVs uptake were evaluated in vitro.
- Human CDC-EVs were fluorescently labeled using the membrane dye DiD and were added to Jurkat T cells (Jurkat, Clone E6-; ATTC® TIN-152TM). Uptake was measured by flow cytometry 1 hour, 4 hours, or overnight after addition of EVs.
- Jurkat T cells tested positive for DmiD fluorescence at the different times tested, indicating that they uptake CDC-EVs ( FIG. 18 ).
- CDC-EVs were able to down regulate PHA-induced CD4+ and CD8+ T cell proliferation. CDC-EVs-induced down regulation of T cells proliferation was dose dependent, and at the highest used dose (20 ⁇ 10 9 particles) CDC-EVs were more potent in down regulating ongoing response than their parental cells, as shown in FIG. 19 .
- CDC-EV-induced immune modulation is likely through direct effects since similar results were obtained when purified CD3+ T cells were used instead of PBMC within the same experimental settings. Indeed, CDC-EVs were able to down regulate PHA-induced expression of CDC69 and/or HLA-DR on T cells obtained from 2 different donors, as shown in FIG. 20 .
- CDC-EVs are potent immune modulators.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Vascular Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a method of treating acute or chronic systemic graft-versus-host disease (GVHD) with extracellular vesicles, e.g., exosomes obtained from human cardiospheres or cardiosphere-derived cells (CDCs), wherein systemic GVHD involves, e.g., at least two organs selected from the group consisting of the skin, mucosa, gastrointestinal tract, liver, lungs, joints and fascia, genitalia, and eyes. The present invention also provides a pharmaceutical formulation comprising extracellular vesicles, e.g., exosomes obtained from human cardiospheres or CDCs, for systemic administration, e.g., intravenous infusion, to a human subject in need of treatment of systemic GVHD.
Description
- This application is a continuation of U.S. patent application Ser. No. 16/610,859, which is a U.S. national stage filing of International Patent Application No. PCT/US2018/031257, which was filed on May 4, 2018, and which claims priority to U.S. Provisional Application No. 62/506,880, which was filed on May 16, 2017, and U.S. Provisional Application No. 62/502,474, which was filed on May 4, 2017, all of which are incorporated herein by reference.
- Graft-versus-host disease (GVHD) occurs when cells transplanted from a non-identical donor (typically bone marrow, T-cell, and/or hematopoietic stem cell donor; the graft) recognize and mount a deleterious immune response against antigens found in the transplant recipient (the host). See, e.g., Billingham, “The Biology of Graft-Versus-Host Reactions,” Harvey Led, 62:2-1% (1966-1967). The disease presents as a heterogeneous condition involving multiple organs, most commonly the skin, mucosa, gastrointestinal tract, liver and lungs. For patients undergoing allogeneic hematopoietic stem cell transplant (HSCT), GVHD is a significant cause of morbidity and mortality. Due to the large number of variables affecting disease risk, there is a wide range of incidence reported for both acute and chronic GVHD. Up to 80% of patients will develop GVHD at approximately 14-21 days following HSCT (acute), and of those surviving beyond 100 days, between 30 and 70% will develop chronic GVHD. Unsurprisingly, chronic GVHD represents the single leading cause of death in HSCT survivors. See, e.g., Pasquini et al, “2010 Report from the Center for International Blood and Marrow Transplant Research (CIBMTR): Current Uses and Outcomes of Hematopoietic Cell Transplants for Blood and Bone Marrow Disorders,” Clin Transpl, 87-105 (2010).
- Development of GVHD is dependent on the activation of antigen-specific donor T cells that are able to mount a specific immune response targeting host tissues. This event is potentiated by conditioning of the host prior to HSCT in order to suppress the immune system and ensure effective engraftment. Host tissue damage is mediated by cytotoxic T cells involving a variety of mechanisms, including direct cell contact and the production of soluble pro-inflammatory mediators. See, e.g., Ferrara et al, “Graft-Versus-Host Disease,” Lancet, 373: 1550-1561 (2009); Sakoda et al, “Donor-Derived Thymic-Dependent T Cells Cause Chronic Graft-Versus-Host Disease,” Blood, 109: 1756-1764 (2010). Multiple T-helper cell subsets have been shown to be involved, including Thl, Th2, and Thl7. See, e.g., Broady et al, “Cutaneous GVHD is Associated with the Expansion of Tissue-Localized Thl and not Th17 Cells,” Blood, 116:5749-5751 (2010); Murphy et al, “Differential Effects of the Absence of Interferon-Gamma and IL-4 in Acute Graft-Versus-Host Disease After Allogeneic Bone Marrow Transplantation in Mice,” J Clin Invest, 102: 1742-1748 (1998); Nikolic et al., “Th1 and Th2 Mediate Acute Graft-Versus-Host Disease, each with Distinct End-Organ Targets,” J Clin Invest., 105: 1289-1298 (2000). The current understanding of their specific roles is complex: in some models, Thl7 cells have been shown to be sufficient for induction of GVHD, whereas in others their absence has been shown to exacerbate disease. See, e.g., Yi et al, “Absence of
Donor Th1 7 Leads to Augmented Th1 Differentiation and Exacerbated Acute-Graft-Versus-Host Disease,” Blood, 112:2101-2110 (2008); Kappel et al, “IL-17 Contributes to CD4-Mediated Graft-Versus-Host Disease,” Blood, 113:945-952 (2009). - Despite the advances in understanding the immuno-pathological basis of the disease and associated risk factors, and the development of more effective MHC matching and immune conditioning, little progress has been made in decreasing late transplantation-related mortality. The focus of current therapy is general immune suppression using corticosteroids, which has dubious efficacy; sustained amelioration of disease symptoms are only seen in around 50% of patients. See, e.g., Billingham, “The Biology of Graft-Versus-Host Reactions,” Harvey Lect., 62:2-1% (1966-1967). More promising therapies are based on the prophylactic prevention of GVHD, and use T cell targeting agents such as methotrexate and tacrolimus. This lack of success is mainly the result of the failure to reduce the incidence and severity of chronic GVHD.
- Cells release into the extracellular environment diverse types of membrane vesicles of endosomal and plasma membrane origin called exosomes and microvesicles, respectively. These extracellular vesicles represent an important mode of intercellular communication by serving as vehicles for transfer between cells of membrane and cytosolic proteins, lipids, and RNA. See, e.g., Graca Raposo and Willem Stoorvogel, “Extracellular Vesicles: Exosomes, Microvesicles, and Friends,” The Journal of Cell Biology, Vol. 200, No. 4, 373-383 (2013). WO 2014/028493 describes exosomes derived from cardiosphere-derived cells (CDCs) and their therapeutic utility for the repair or regeneration of damaged or diseased cells or tissue, e.g., damaged cardiac tissue. US 2012/0315252 describes CDCs, their derivation from cardiospheres, and their therapeutic utility for increasing the function of a damaged or diseased heart of a mammal. WO 2005/012510 describes cardiospheres, their derivation from human or animal cardiac tissue biopsy samples, and their therapeutic utility in cell transplantation and functional repair of the myocardium or other organs.
- The present invention is based on the surprising discovery by the present inventors that extracellular vesicles, in particular exosomes derived from cardiosphere-derived cells (CDCs), have immunomodulatory capabilities on T cells and are effective in treating systemic graft-versus-host disease (GVHD), as demonstrated for the first time in a relevant mouse model of systemic GVHD. The advantage of the method of the present invention as described herein is that it is a safe, systemically-administered biologic therapy that can improve both survival and end-organ damage (e.g., gastrointestinal tract and eyes) in GVHD by modulating the immune response and reducing inflammation and fibrosis. This causes reduction in end-organ morbidities such as ocular GVHD and weight loss attributable to poor nutrient absorption in the gastrointestinal tract, leading to inter alia improved survival and presumably enhanced quality of life.
- For the purpose of the present invention, the term “systemic GVHD” is used interchangeably with “GVHD”, and refers to acute or chronic GVHD requiring or amenable to treatment by systemic administration of extracellular vesicles, e.g. exosomes and/or microvesicles, derived from CDCs.
- Generally, the present invention provides a method of safely treating systemic GVHD in a subject in need thereof, the method comprising systemically administrating to the subject a therapeutically effective amount of extracellular vesicles, e.g., exosomes and/or microvesicles, derived from CDCs, wherein systemic GVHD is a syndrome involving multiple organs, most commonly the skin, mucosa, gastrointestinal tract, liver, and lungs, wherein cells originating from a donor (typically bone marrow, T-cell, and/or hematopoietic stem cell donor) recognize and mount a deleterious immune response against antigens found in the immunocompromised recipient.
- According to one aspect of the present invention, systemic administration of a therapeutically effective amount of extracellular vesicles, e.g., exosomes and/or microvesicles, derived from CDCs, results in treatment of systemic GVHD with respect to at least one organ selected from the group consisting of the skin, mucosa, gastrointestinal tract, liver, and lungs. Alternatively, according to the present invention, said administration of a therapeutically effective amount of extracellular vesicles results in treatment of systemic GVHD with respect to at least two organs selected from the group consisting of the skin, mucosa, gastrointestinal tract, liver, and lungs.
- According to another aspect of the present invention, systemic administration of a therapeutically effective amount of extracellular vesicles, e.g., exosomes and/or microvesicles, derived from CDCs, results in treatment of systemic GVHD with respect to at least one organ selected from the group consisting of the skin, mucosa, gastrointestinal tract, liver, lungs, joints and fascia, and genitalia. Alternatively, according to the present invention, said administration of a therapeutically effective amount of extracellular vesicles results in treatment of systemic GVHD with respect to at least two organs selected from the group consisting of the skin, mucosa, gastrointestinal tract, liver, lungs, joints and fascia, and genitalia.
- According to another aspect of the present invention, systemic administration of a therapeutically effective amount of extracellular vesicles, e.g., exosomes and/or microvesicles, derived from CDCs, results in treatment of systemic GVHD with respect to at least one organ selected from the group consisting of the skin, mucosa, gastrointestinal tract, liver, lungs, joints and fascia, and genitalia, and the eyes.
- According to another aspect of the present invention, systemic administration of a therapeutically effective amount of extracellular vesicles, e.g., exosomes and/or microvesicles, derived from CDCs, results in treatment of systemic GVHD with respect to the eyes.
- According to the present invention, a therapeutically effective amount of extracellular vesicles, e.g., exosomes and/or microvesicles, derived from CDCs, is systemically administered one or more times after the subject has undergone HSCT. In some embodiments, a therapeutically effective amount of extracellular vesicles is systemically administered to the subject less than, e.g., 1 hour post HSCT. In some embodiments, a therapeutically effective amount of extracellular vesicles is systemically administered to the subject less than, e.g., 1-24 hours post HSCT. In some embodiments, a therapeutically effective amount of extracellular vesicles is systemically administered to the subject less than, e.g., 24-48 hours post HSCT. In some embodiments, a therapeutically effective amount of extracellular vesicles is systemically administered to the subject, e.g., 1-2 weeks post HSCT. In some embodiments, a therapeutically effective amount of extracellular vesicles is systemically administered to the subject, e.g., 2-3 weeks after post HSCT. In some embodiments, a therapeutically effective amount of extracellular vesicles is systemically administered to the subject, e.g., 4-8 weeks post HSCT. In some embodiments, a therapeutically effective amount of extracellular vesicles is systemically administered to the subject, e.g., 1, 2, 3, 4, 5, 6, 7, and/or 8 weeks after HSCT, one or more times, e.g., 7 days apart between successive administrations.
- According to the present invention, said subject is a mammal, e.g., a human; said systemic administration is via, e.g., intra-vascular administration, intraventricular administration, intrathecal administration, or intraperitoneal administration, wherein said intra-vascular administration is, e.g., intravenous, intra-arterial, or intracoronary infusion or injection.
- According to the present invention, said extracellular vesicles are exosomes, microvesicles, membrane particles, membrane vesicles, exosome-like vesicles, ectosomes, ectosome-like vesicles, exovesicles, epididimosomes, argosomes, promininosomes, prostasomes, dexosomes, texosomes, archeosomes, oncosomes, or the like.
- According to an embodiment of the present invention, said extracellular vesicles are derived from CDCs cultured in serum-free medium (e.g., IMDM) and incubated at about 5% O2 for about 15 days, wherein said extracellular vesicles are obtained after filtering CDC condition medium containing extracellular vesicles through a 1000 kDa pore sized filter. More generally, according to the present invention, said extracellular vesicles are derived from CDCs cultured in serum-containing or serum-free medium and incubated at 2-20% O2 for 1-15 days, wherein said extracellular vesicles are obtained after filtering CDC condition medium containing extracellular vesicles through a 3-1000 kDa (e.g., 10 kDa) pore sized filter. Alternatively, extracellular vesicles are obtained by precipitation with polyethylene glycol (e.g., 25% PEG).
- According to the present invention, extracellular vesicles, e.g., exosomes, are formulated in a crystalloid solution (e.g., Plasmalyte, normal saline), aqueous solution, gel, ointment, cream, topical or implantable hydrogel, powder, sustained-release polymer (e.g., PLGA and PLA), polyethylene glycol (PEG)-containing solution, suspension, emulsion, as part of a drug delivery device, insert, patch, or the like. In several embodiments, prior to use, extracellular vesicles, e.g., exosomes, are resuspended in an appropriate buffer, e.g., sterile PBS with or without human serum albumin. In some embodiments, exosomes can be stored for future use, e.g., frozen at −80° C.
- In several embodiments, extracellular vesicles, e.g., exosomes, are derived from human or animal cells. In several embodiments, extracellular vesicles, e.g., exosomes, are prepared from cardiospheres or CDCs. In some embodiments, extracellular vesicles, e.g., exosomes, are prepared from regenerative stem cells such as embryonic stem cells, pluripotent stem cells, multipotent stem cells, induced pluripotent stem cells, post-natal stem cells, adult stem cells, mesenchymal stem cells, hematopoietic stem cells, endothelial stem cells, epithelial stem cells, neural stem cells, cardiac stem cells including cardiac progenitor cells, bone marrow-derived stem cells, adipose-derived stem cells, hepatic stem cells, peripheral blood derived stem cells, cord blood-derived stem cells, placental stem cells, or the like.
- In several embodiments, extracellular vesicles, e.g., exosomes, are modified (e.g., genetically or otherwise) to direct them to a specific target site. For example, a modification may, in some embodiments, comprise inducing expression of a specific cell-surface marker on the exosome, which results in specific interaction with a receptor on a desired target tissue. In one embodiment, the native contents of the exosome are removed and replaced with, or supplemented with, desired exogenous proteins and/or nucleic acids.
- In several embodiments, extracellular vesicles, e.g., exosomes, include one or more microRNAs selected from: miR-146a, miR-148a, miR-22, miR-24, miR-210, miR-150, miR-140-3p, miR-19a, miR-27b, miR-19b, miR-27a, miR-376c, miR-128, miR-320a, miR-143, miR-21, miR-130a, miR-9, miR-185, and miR-23a. In a preferred embodiment, extracellular vesicles, e.g., exosomes, comprise miR-146a and miR-210. In several embodiments, extracellular vesicles, e.g., exosomes, include one or more microRNAs selected from: hsa-miR-23α-3p, hsa-miR-130a-3p, hsa-miR-21-5p, hsa-miR-4516, hsa-let-7a-5p, hsa-miR-125b-5p, hsa-miR-199a-3p, hsa-miR-199b-3p, hsa-miR-22-3p, hsa-miR-24-3p, hsa-miR-1290, hsa-miR-320e, hsa-miR-423-5p, hsa-miR-22-3p, hsa-miR-222-3p (also known as miR-221-3p), hsa-miR-100-5p, hsa-miR-337-5p, hsa-miR-27b-3p, hsa-miR-1915-3p, and hsa-miR-29b-3p, hsa-miR-25-3p (also known as miR-92a-3p).
- In several embodiments, extracellular vesicles, e.g., exosomes, contain biological proteins, e.g., transcription factors, cytokines, growth factors, and similar proteins capable of modulating signaling pathways in a target cell. In some embodiments, the biological protein is capable of facilitating regeneration and/or improved function of a tissue. In some embodiments, the biological protein is capable of modulating pathways related to Irak1, Traf6, toll-like receptor (TLR) signaling pathway, NOX-4, SMAD-4, and/or TGF-β. In some embodiments, the biological protein is related to exosome formation and packaging of cytosolic proteins such as Hsp70, Hsp90, 14-3-3 epsilon, PKM2, GW182 and AG02. In some embodiments, extracellular vesicles, e.g., exosomes, contain signaling lipids, e.g., ceramide and derivatives.
- In several embodiments, extracellular vesicles, e.g., exosomes, express tetraspanins, e.g., CD63, CD81, CD82, CD53, and/or CD37. In some embodiments, extracellular vesicles, e.g., exosomes, express one or more lipid raft associated proteins (e.g., glycosylphosphatidylinositol-anchored proteins and flotillin), cholesterol, sphingomyelin, and/or hexosylceramides.
- In several embodiments, extracellular vesicles, e.g., exosomes, have a diameter of, e.g., about 15-250 nm, about 15-205 nm, about 90-220 nm, about 30-200 nm, about 20-150 nm, about 70-150 nm, or about 40-100 nm. In several embodiments, extracellular vesicles, e.g., microvesicles, have a diameter of, e.g., about 100-1000 nm.
- In several embodiments, extracellular vesicles, e.g., exosomes, are purified such that contaminants or undesired compounds are removed from the exosomes. In some embodiments, the patient is administered substantially purified exosomes such that about 50% to 90%, or up to 100%), of the contaminants are removed from the exosomes. In some embodiments, an exosome preparation is essentially free of non-exosome components.
- In several embodiments, extracellular vesicles, e.g., exosomes, are administered in combination with one or more additional agents. For example, in several embodiments, the exosomes are administered in combination with one or more proteins or nucleic acids derived from the exosome. In several embodiments, the cells from which the exosomes are isolated are administered in conjunction with the exosomes. In several embodiments, such an approach advantageously provides an acute and more prolonged duration of exosome delivery (e.g., acute based on the actual exosome delivery and prolonged based on the cellular delivery, the cells continuing to secrete exosomes post-delivery).
- In several embodiments, the dose of extracellular vesicles, e.g., exosomes ranges about 1.0×105 to about 1.0×1010 exosomes. In certain embodiments, the exosome dose is administered on a per kilogram basis, e.g., about 1.0×105 exosomes/kg to about 1.0×109 exosomes/kg. In additional embodiments, exosomes are delivered in an amount based on the mass of the target tissue, e.g., about 1.0×105 exosomes/gram of target tissue to about 1.0×109 exosomes/gram of target tissue. In several embodiments, exosomes are administered based on a ratio of the number of exosomes to the number of cells in a particular target tissue. If exosomes are to be administered in conjunction with the concurrent therapy (e.g., cells that can still shed exosomes, pharmaceutical therapy, nucleic acid therapy, and the like) the dose of exosomes administered can be adjusted accordingly (e.g., increased or decreased as needed to achieve the desired therapeutic effect).
- The present invention further provides a formulation comprising extracellular vesicles for use in the treatment of systemic GVHD according to the aforementioned method.
- The present invention further provides a use of the aforementioned formulation for treating systemic GVHD according to the aforementioned method.
-
FIG. 1 is a diagram showing how systemic GVHD is induced in BALB/c mice. -
FIG. 2A is a photograph showing an example ofGrade 0 for the posture criterion of the GVHD score. -
FIG. 2B is a photograph showing an example ofGrade 1 for the posture criterion of the GVHD score. -
FIG. 2C is a photograph showing an example ofGrade 2 for the posture criterion of the GVHD score. -
FIG. 3 A is a photograph showing an example ofGrade 0 for the fur texture criterion of the GVHD score. -
FIG. 3B is a photograph showing an example ofGrade 1 for the fur texture criterion of the GVHD score. -
FIG. 3C is a photograph showing an example ofGrade 2 for the fur texture criterion of the GVHD score. -
FIG. 4A is a photograph showing an example ofGrade 0 for the skin integrity criterion of the GVHD score. -
FIG. 4B is a photograph showing an example ofGrade 1 for the skin integrity criterion of the GVHD score. -
FIG. 4C is a photograph showing an example ofGrade 2 for the skin integrity criterion of the GVHD score. -
FIG. 5 schematically illustrates the study design for evaluating the efficacy of extracellular vesicles to treat systemic GVHD. -
FIG. 6A graphically shows the effects of intravenous administration of extracellular vesicles on the weight of the mouse model of systemic GVHD. -
FIG. 6B shows the same data ofFIG. 6A as AUC to enable effective comparison of groups by statistical test. -
FIG. 7A graphically shows the effects of intravenous administration of extracellular vesicles on the overall GVHD score. -
FIG. 7B shows the same data ofFIG. 7A as AUC to enable effective comparison of groups by statistical test. -
FIG. 8A graphically shows the effects of intravenous administration of extracellular vesicles on the posture criterion of the GVHD score. -
FIG. 8B graphically shows the effects of intravenous administration of extracellular vesicles on the activity criterion of the GVHD score. -
FIG. 8C graphically shows the effects of intravenous administration of extracellular vesicles on the fur activity criterion of the GVHD score. -
FIG. 8D graphically shows the effects of intravenous administration of extracellular vesicles on the skin integrity criterion of the GVHD score. -
FIG. 9 graphically shows the effects of intravenous administration of extracellular vesicles on the survival of the mouse model of systemic GVHD. -
FIGS. 10A-B graphically show the effects of intravenous administration of extracellular vesicles on the diarrhea incidence of the mouse model of systemic GVHD. -
FIGS. 11A-C graphically show the effects of intravenous administration of extracellular vesicles on the eye inflammation of the mouse model of systemic GVHD. -
FIG. 12 graphically shows the effects of intravenous administration of extracellular vesicles on the colitis scores of the mouse model of systemic GVHD. -
FIG. 13 graphically shows the same data as inFIG. 12 as sum colitis scores. -
FIG. 14 graphically shows the effects of intravenous administration of extracellular vesicles on the colon histopathology severity scores of the mouse model of systemic GVHD. -
FIG. 15 graphically shows the effects of intravenous administration of extracellular vesicles on the eye average histopathology scores of the mouse model of systemic GVHD. -
FIG. 16 is a western blot showing CDC-EVs' contents of recognized exosomes markers. -
FIG. 17 graphically shows the expression of immune molecules involved in T and natural killer (NK) immune response on CDC-EVs. -
FIG. 18 . Shows in vitro update of CDC-EVs in Jurkat T cells. -
FIG. 19 shows the immune modulation of PHA-induced T cells proliferation by and CDC-EVs. -
FIG. 20 graphically shows the down-regulation of PHA-induced CD69 and/or HLA-DR expression by CDCs and CDC-EVs. -
FIG. 21 graphically shows that CDC-EVs down regulate PHA-induced T cells - proliferation.
-
FIG. 22 graphically shows that immune modulation of PHA-induced CD4+ and CD8+ T cells proliferation by CDC-EVs. - GVHD has been classically divided into acute and chronic variants based upon the time of onset using a cutoff of 100 days. Clinical manifestations of chronic GVHD include skin involvement resembling lichen planus or the cutaneous manifestations of scleroderma, dry oral mucosa with ulcerations and sclerosis of the gastrointestinal tract, and a rising serum bilirubin concentration. In contrast, patients with acute GVHD commonly demonstrate a classic maculopapular rash, abdominal cramps with diarrhea, and a rising serum bilirubin concentration. However, this conventional division has been challenged by the recognition that signs of acute and chronic GVHD may occur outside of these designated periods. This observation has led to the increased use of clinical findings, rather than a set time period, to differentiate between acute and chronic GVHD. The widely accepted National Institutes of Health (NIH) consensus criteria for the diagnosis of GVHD include an overlap syndrome in which diagnostic or distinctive features of chronic GVHD and acute GVHD appear together. See, e.g., Filipovich et al., “National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease: I. Diagnosis and Staging Working Group Report,” Biol
- Blood Marrow Transplant, 11(12):945 (2005).
- The NIH consensus criteria for identifying signs and symptoms of chronic GVHD are summarized in Table 1. See, e.g., Jagasia et al., “National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report,” Biol Blood Marrow Transplant, 21:389 (2015).
-
TABLE 1 Mouth: Mild symptoms with Moderate symptoms Severe symptoms with Lichen planus-like disease signs but not with disease signs with disease signs on features limiting oral intake partial limitation of examination with significantly oral intake major limitation of oral intake Gastrointestinal Tract: Symptoms without Symptoms associated Symptoms associated Esophageal web/proximal significant weight loss with mild to moderate with significant weight stricture or ring; (<5%) weight loss (5-15%), or loss(>15%); requires dysphagia; anorexia; moderate diarrhea nutritional supplement nausea; vomiting; without significant for most calorie needs, diarrhea; weight loss; interference with daily or esophageal dilation, failure to thrive living or severe diarrhea with significant interference with daily living Liver Normal total bilirubin Elevated total bilirubin Elevated total bilirubin with alanine but 3 mg/dL, or but >3 mg/dL aminotransferase ALT > 5ULN (ALT) 3-5 × upper limit of normal (ULN), or alkaline phosphatase (AP) 3 × ULN Lungs: Mild symptoms Moderate symptoms Severe symptoms Pulmonary function tests (shortness of breath (shortness of breath (shortness of breath at after climbing one after walking on flat rest; requiring 02); flight of steps); ground); FEV1 = 40- FEV1 39% forced expiratory 59% volume in 1 second (FEV1) 60-79% Joints and Fascia Mild tightness of arms Tightness of arms or Contractures with or legs, normal or mild legs, or joint significant decrease of decreased range of contractures, erythema ROM, and significant motion (ROM), and thought due to fasciitis, limitation of ADL not affecting ADL decreased ROM, and (unable to tie shoes, mild to moderate button shirts, dress self, limitation of ADL etc.) Genital Tract Mild signs and females Moderate signs and Severe signs with or with or without may have symptoms without symptoms discomfort on exam with discomfort on exam Eyes: Mild dry eye Moderate dry eye Severe dry eye Keratoconjunctivitis sicca symptoms not affecting symptoms partially symptoms significantly (KCS) confirmed by activities of daily affecting ADL; affecting ADL; ophthalmologist living (ADL); requiring lubricant eye Special eyeware to requiring lubricant eye drops >3 × per day or relieve pain, or unable drops 3 × per day punctal plugs; without to work because of new vision impairment ocular symptoms, or due to KCS loss of vision due to KCS - Patients diagnosed with chronic GVHD are then subclassified based upon the presence or absence of features of acute GVHD into one of two categories: (i) classic chronic GV.HD: Features of chronic GVH-D are present without signs or symptoms of acute GVH-D; (ii) overlap syndrome: Features of both chronic GVHD and acute GVHD are present.
- Features of acute GVHD seen in the overlap syndrome include changes in the skin (skin erythema, maculopapular rash, pruritus), mouth (gingivitis, mucositis, oral erythema, oral pain), gastrointestinal symptoms (anorexia, nausea, vomiting, diarrhea, weight loss, failure to thrive), liver dysfunction (elevations in bilirubin, alkaline phosphatase, ALT, or AST), and organizing pneumonia (also called bronchiolitis obliterans organizing pneumonia).
- For the purpose of the present invention, terms such as “treating” and “treatment” as used herein refer to therapeutic measures that cure, slow down, lessen symptoms of, and/or halt progression of a diagnosed pathologic condition or disorder. For instance, a subject is successfully “treated” according to the methods of the present invention if the subject shows clinical improvement according to the NIH consensus criteria for identifying signs and symptoms of chronic GVHD.
- Cardiospheres are undifferentiated cardiac cells that grow as self-adherent clusters as described in WO 2005/012510, and Messina et al, “Isolation and Expansion of Adult Cardiac Stem Cells From Human and Murine Heart,” Circulation Research, 95: 911-921 (2004), the disclosures of which are herein incorporated by reference in their entirety.
- Briefly, heart tissue can be collected from a patient during surgery or cardiac biopsy. The heart tissue can be harvested from the left ventricle, right ventricle, septum, left atrium, right atrium, crista terminalis, right ventricular endocardium, septal or ventricle wall, atrial appendages, or combinations thereof. A biopsy can be obtained, e.g., by using a percutaneous bioptome as described in, e.g., U.S. Patent Application Publication Nos. 2009/012422 and 2012/0039857, the disclosures of which are herein incorporated by reference in their entirety. The tissue can then be cultured directly, or alternatively, the heart tissue can be frozen, thawed, and then cultured. The tissue can be digested with protease enzymes such as collagenase, trypsin and the like. The heart tissue can be cultured as an explant such that cells including fibroblast-like cells and cardiosphere-forming cells grow out from the explant. In some instances, an explant is cultured on a culture vessel coated with one or more components of the extracellular matrix (e.g., fibronectin, laminin, collagen, elastin, or other extracellular matrix proteins). The tissue explant can be cultured for about 1, 2, 3, 4, or more weeks prior to collecting the cardiosphere-forming cells. A layer of fibroblast-like cells can grow from the explant onto which cardiosphere-forming cells appear. Cardiosphere-forming cells can appear as small, round, phase-bright cells under phase contrast microscopy. Cells surrounding the explant including cardiosphere-forming cells can be collected by manual methods or by enzymatic digestion. The collected cardiosphere-forming cells can be cultured under conditions to promote the formation of cardiospheres. In some aspects, the cells are cultured in cardiosphere-growth medium comprising buffered media, amino acids, nutrients, serum or serum replacement, growth factors including but not limited to EGF and bFGF, cytokines including but not limited to cardiotrophin, and other cardiosphere promoting factors such as but not limited to thrombin. Cardiosphere-forming cells can be plated at an appropriate density necessary for cardiosphere formation, such as about 20,000-100,000 cells/mL. The cells can be cultured on sterile dishes coated with poly-D-lysine, or other natural or synthetic molecules that hinder the cells from attaching to the surface of the dish. Cardiospheres can appear spontaneously about 2-7 days or more after cardiosphere-forming cells are plated.
- CDCs are a population of cells generated by manipulating cardiospheres in the manner as described in, e.g., U.S. Patent Application Publication No. 2012/0315252, the disclosures of which are herein incorporated by reference in their entirety. For example, CDCs can be generated by plating cardiospheres on a solid surface which is coated with a substance which encourages adherence of cells to a solid surface of a culture vessel, e.g., fibronectin, a hydrogel, a polymer, laminin, serum, collagen, gelatin, or poly-D-lysine, and expanding same as an adherent monolayer culture. CDCs can be repeatedly passaged, e.g., passaged two times or more, according to standard cell culturing methods.
- Exosomes are vesicles formed via a specific intracellular pathway involving multivesicular bodies or endosomal-related regions of the plasma membrane of a cell. Exosomes can range in size from approximately 20-150 nm in diameter. In some cases, they have a characteristic buoyant density of approximately 1.1-1.2 g/mL, and a characteristic lipid composition. Their lipid membrane is typically rich in cholesterol and contains sphingomyelin, ceramide, lipid rafts and exposed phosphatidylserine. Exosomes express certain marker proteins, such as integrins and cell adhesion molecules, but generally lack markers of lysosomes, mitochondria, or caveolae. In some embodiments, the exosomes contain cell-derived components, such as but not limited to, proteins, DNA and RNA (e.g., microRNA and noncoding RNA). In some embodiments, exosomes can be obtained from cells obtained from a source that is allogeneic, autologous, xenogeneic, or syngeneic with respect to the recipient of the exosomes.
- Certain types of RNA, e.g., microRNA (miRNA), are known to be carried by exosomes. miRNAs function as post-transcriptional regulators, often through binding to complementary sequences on target messenger RNA transcripts (mRNAs), thereby resulting in translational repression, target mRNA degradation and/or gene silencing. For example, as described in WO 2014/028493, miR146a exhibits over a 250-fold increased expression in CDCs, and miR210 is upregulated approximately 30-fold, as compared to the exosomes isolated from normal human dermal fibroblasts.
- Exosomes derived from cardiospheres and CDCs are described in, e.g., WO 2014/028493, the disclosures of which are herein incorporated by reference in their entirety. Methods for preparing exosomes can include the steps of: culturing cardiospheres or CDCs in conditioned media, isolating the cells from the conditioned media, purifying the exosome by, e.g., sequential centrifugation, and optionally, clarifying the exosomes on a density gradient, e.g., sucrose density gradient. In some instances, the isolated and purified exosomes are essentially free of non-exosome components, such as components of cardiospheres or CDCs. Exosomes can be resuspended in a buffer such as a sterile PBS buffer containing 0.01-1% human serum albumin. The exosomes may be frozen and stored for future use.
- Exosomes can be prepared using a commercial kit such as, but not limited to the ExoSpin™ Exosome Purification Kit, Invitrogen® Total Exosome Purification Kit, PureExo® Exosome Isolation Kit, and ExoCap™ Exosome Isolation kit. Methods for isolating exosome from stem cells are found in, e.g., Tan et al, Journal of Extracellular Vesicles, 2:22614 (2013); Ono et al., Sci Signal, 7(332):ra63 (2014) and U.S. Application Publication Nos. 2012/0093885 and 2014/0004601. Methods for isolating exosome from cardiosphere-derived cells are found in, e.g., Ibrahim et al, Stem Cell Reports, 2:606-619 (2014). Collected exosomes can be concentrated and/or purified using methods known in the art. Specific methodologies include ultracentrifugation, density gradient, HPLC, adherence to substrate based on affinity, or filtration based on size exclusion.
- For example, differential ultracentrifugation has become a leading technique wherein secreted exosomes are isolated from the supernatants of cultured cells. This approach allows for separation of exosomes from nonmembranous particles, by exploiting their relatively low buoyant density. Size exclusion allows for their separation from biochemically similar, but biophysically different microvesicles, which possess larger diameters of up to 1,000 nm.
- Differences in flotation velocity further allows for separation of differentially sized exosomes. In general, exosome sizes will possess a diameter ranging from 30-200 nm, including sizes of 40-100 nm. Further purification may rely on specific properties of the particular exosomes of interest. This includes, e.g., use of immunoadsorption with a protein of interest to select specific vesicles with exoplasmic or outward orientations.
- Among current methods, e.g., differential centrifugation, discontinuous density gradients, immunoaffinity, ultrafiltration and high performance liquid chromatography (HPLC), differential ultracentrifugation is the most commonly used for exosome isolation. This technique utilizes increasing centrifugal force from 2000×g to 10,000×g to separate the medium- and larger-sized particles and cell debris from the exosome pellet at 100,000×g. Centrifugation alone allows for significant separation/collection of exosomes from a conditioned medium, although it is insufficient to remove various protein aggregates, genetic materials, particulates from media and cell debris that are common contaminants. Enhanced specificity of exosome purification may deploy sequential centrifugation in combination with ultrafiltration, or equilibrium density gradient centrifugation in a sucrose density gradient, to provide for the greater purity of the exosome preparation (
flotation density 1. 1-1.2 g/mL) or application of a discrete sugar cushion in preparation. - Importantly, ultrafiltration can be used to purify exosomes without compromising their biological activity. Membranes with different pore sizes—such as 100 kDa molecular weight cutoff (MWCO) and gel filtration to eliminate smaller particles—have been used to avoid the use of a nonneutral pH or non-physiological salt concentration. Currently available tangential flow filtration (TFF) systems are scalable (to >10,000 L), allowing one to not only purify, but concentrate the exosome fractions, and such approaches are less time consuming than differential centrifugation. HPLC can also be used to purify exosomes to homogeneously sized particles and preserve their biological activity as the preparation is maintained at a physiological pH and salt concentration.
- Other chemical methods have exploit differential solubility of exosomes for precipitation techniques, addition to volume-excluding polymers (e.g., polyethylene glycols (PEGs)), possibly combined additional rounds of centrifugation or filtration. For example, a precipitation reagent, ExoQuick®, can be added to conditioned cell media to quickly and rapidly precipitate a population of exosomes, although re-suspension of pellets prepared via this technique may be difficult. Flow field-flow fractionation (F1FFF) is an elution-based technique that is used to separate and characterize macromolecules (e.g., proteins) and nano- to micro-sized particles (e.g., organelles and cells) and which has been successfully applied to fractionate exosomes from culture media.
- Beyond these techniques relying on general biochemical and biophysical features, focused techniques may be applied to isolate specific exosomes of interest. This includes relying on antibody immunoaffinity to recognizing certain exosome-associated antigens. As described, exosomes further express the extracellular domain of membrane-bound receptors at the surface of the membrane. This presents a ripe opportunity for isolating and segregating exosomes in connections with their parental cellular origin, based on a shared antigenic profile. Conjugation to magnetic beads, chromatography matrices, plates or microfluidic devices allows isolating of specific exosome populations of interest as may be related to their production from a parent cell of interest or associated cellular regulatory state. Other affinity-capture methods use lectins which bind to specific saccharide residues on the exosome surface.
- The present invention is further described with reference to the following non-limiting examples.
- CDCs were prepared as described in U.S. Patent Application Publication No. 2012/0315252, the disclosures of which are herein incorporated by reference in their entirety.
- In brief, heart biopsies were minced into small fragments and briefly digested with collagenase. Explants were then cultured on 20 mg/mL fibronectin-coated dishes. Stromal-like flat cells and phase-bright round cells grew out spontaneously from tissue fragments and reached confluency by 2-3 weeks. These cells were harvested using 0.25% trypsin and were cultured in suspension on 20 mg/mL poly-d-lysine to form self-aggregating cardiospheres. CDCs were obtained by plating and expanding the cardiospheres on a fibronectin-coated flask as an adherent monolayer culture. All cultures were maintained at 5% 02, 5% C02 at 37° C., using IMDM basic medium supplemented with 10% FBS, 1% penicillin/streptomycin, and 0.1 mL 2-mercaptoethanol. CDCs were grown to 100% confluency on a fibronectin-coated flask to
passage 5. - When the CDCs reached the desired confluency, the flask was washed three times with PBS. CDCs were treated with serum-free medium (IMDM) and were incubated at 37° C. at 5% 02, 5% C02 for 15 days. After 15 days, the conditioned medium was collected in 225 mL BD Falcon polypropylene conical tubes (BD 352075—Blue Top) and centrifuged at 2,000 rpm for 20 minutes at 4° C. to remove cells and debris (care was taken not to disturb the pellet). The conditioned medium was run through a 0.45 μπι membrane filter. The conditioned medium was concentrated using centrifugal filter. A 3 KDa Centricon Plus-70 Centrifugal Filter was pre-rinsed with 10-25 mL of molecular grade water and was centrifuged at 3220 g for five minutes at 18° C. Once the filter was rinsed, all remaining water was carefully removed without touching the filter. 15 mL of the conditioned medium was added to the filter and was centrifuged at 3220 g for 45 minutes at 18° C. After the initial spin, the remaining medium was mixed by pipetting and then spun again until the desired concentration was reached. The final sample was then run through a 0.22 μm syringe filter. 25 μL of the concentrated conditioned medium was diluted in 975 μL of PBS for particle count using the Nanosight. Another 100 μL of the concentrated conditioned medium was used to measure protein concentration. Protein was quantified using the DC protein Assay. In some cases, historical data was used to calculate the concentration of protein in the ultra-filtration by centrifugation (UFC) sample. The concentrated conditioned medium was used immediately or was stored at −80° C.
- The appropriate volume of 25% PEG was added to the filtered concentrated conditioned medium. The samples were incubated at 4° C. for 12-16 hours on an orbital shaker. Once incubation was complete, the samples were centrifuged at 1500 g for 30 minutes at 4° C. The supernatant was carefully removed without disrupting the pellet. The pellet was resuspended in the desired volume of serum-free medium and sampled for particle count.
- A) 10 KDa & 1000 KDa Method
- CDC-EV (10 KDa or 1000 KDa) drug substance is obtained after filtering CDC conditioned medium (CM) containing EVs through a 10 KDa or 1000 KDa pore size filter. The final product, composed of secreted EVs and concentrated CM, is formulated in PlasmaLyte A and stored frozen.
- B) MSC-EVs
- Extracellular vesicles originating from human bone marrow mesenchymal stem cells (MSC-EVs) are obtained after filtering MSC CM containing EVs through a 10 KDa pore size filter following a similar process as for CDC-EV production. MSC-EVs are a non-cellular, filter sterilized product obtained from human MSCs cultured under defined, serum-free conditions. The final product, composed of secreted EVs and concentrated CM, is formulated in PlasmaLyte A and stored frozen. The frozen final product is “ready to use” for direct subconjunctival injection after thawing.
- C) Newt-EVs
- Extracellular vesicles originating from newt Al cell line (Newt-EVs) are obtained after filtering Al cell line CM containing EVs through a 10 KDa pore size filter following a similar process as for CDC-EV production. Newt-EVs are a non-cellular, filter sterilized product obtained from newt Al cells cultured under defined, serum-free conditions. The final product, composed of secreted EVs and concentrated CM, is formulated in PlasmaLyte A and stored frozen. The frozen final product is ready to use for direct subconjunctival injection after thawing.
- The test article is a non-cellular, filter sterilized product obtained from human CDCs cultured under defined, serum-free conditions, prepared as exemplified in Examples 1-4. The general characteristics of the test article are summarized in Table 2.
-
TABLE 2 Characteristics Description Test article CDC-EVs Control article PlasmaLyte A solution (Baxter) Pharmaceutical form CDC-EV suspension in PlasmaLyte for injection Dosage/Strength Low dose: 1.00 × 109 particles/200 μL (1×/week); High dose: 1.00 × 1010 particles/200 μL (1×/week) for Days switched to 3.33 × l09 particles/200 μL (2×/week) for Days Fill/Vial Size 0.4 mL per 2 mL vial Product Container CellSeal ® closed-system vial with needleless luer fittings Storage Conditions Frozen at −80° C. - Individual exosome vials were thawed at 4° C. or on ice. After each aliquot was completely thawed it was mixed gently (−6-8 times, avoiding excessive bubbling/foaming) using a micropipette, or an insulin/Hamilton type syringe with an integrated needle, prior to first administration.
- The test and control articles were thawed for dosing overnight or on the day of dosing, and kept on wet ice throughout the dosing procedures.
- Recipient BALB/c mice (n=45, male, 6-8 weeks of age) and donor C57BL/6 (n=30, male 6-10 weeks) were obtained from Charles River Laboratories (Wilmington, MA). Animals were acclimatized prior to study commencement. During this period, the animals were observed daily in order to reject any that presented in poor condition.
- The study was performed in animal rooms provided with HEPA filtered air at a temperature of 70±5° F. and 50%±20% relative humidity. Animals were housed in groups of 15 per cage. Animal rooms were set to maintain a minimum of 12-15 air changes per hour. The room was on an automatic timer for a light/dark cycle of 12 hours on and 12 hours off with no twilight. Sterile Alpha-dri® bedding was used. Animals were fed with LabDiet 5053 sterile rodent diet and water was provided ad libitum.
-
FIGS. 1 and 5 illustrate how the animal model of systemic GVHD was generated, based on, e.g., Schroeder and DiPersio, “Mouse Models of Graft-Versus-Host Disease: Advances and Limitations,” Disease Models & Mechanisms, 4:318-333 (2011); van Leeuwen et al, “A Two-Phase Pathogenesis of Graft-Versus-Host Disease in Mice,” Bone Marrow Transplantation, 29: 151-158 (2002), with a few modifications. On Day −1, BALB/c mice were subjected to a single acute dose of 8 Gy of total body irradiation (TBI). OnDay 0, the BALB/c recipients were given an intravenous injection, using a syringe with 30-gauge needle into the tail vein, of a combination of 2×106 splenocytes and T-cell depleted (CD3−)bone marrow cells 5×106 in sterile 1×PBS. Bone marrow (BM) and splenic cells (SC) were obtained from donor male C57BL/6 mice. The bone marrow cells were isolated using standard flushing practices and T-cell depleted using the cell surface T-cell antigen CD3, with a CD3-biotin kit from Miltenyi Biotec (130-093-021). Recipient animals were randomized into 3 groups of 15 animals each. - Following TBI on Day −1 up to Day 8, all animals were given supplemental high calorie highly palatable food in a dish on the bottom of the cage. Following transfer on
Day 0, and then again as needed, all animals were given 1 mL/animal/day of supplemental fluids (warmed ringers solution) via subcutaneous injection. An additional 1 mL fluid may have been given in the afternoon on an as needed basis. Any animal exceeding −15% body weight loss was given highly palatable soft food and 1 mL supplemental fluids (warmed ringers solution) via subcutaneous injection. - Animals were dosed with the vehicle or the test article as detailed in Table 3 and as illustrated in
FIG. 5 . -
TABLE 3 Cell TBI transfer Group n (Day −1) (Day 0) Treatment Schedule Sacrifice Collections 1 15 8 Gy 5 × 106 BM PlasmaLyte 21, 28, 35, 43 Day 54Plasma, and and 50 liver, lung, 2 × 106 SC (I×/week) eye, femur, colon 2 15 8 Gy 5 × 106 BM Low dose: 21, 28, 35, 43 Day 54Plasma, and 1.00 × 109 and 50 liver, lung, 2 × 106 SC CDC-EVs (I×/week) eye, femur, colon 3 15 8 Gy 5 × 106 BM High dose: 1.00 × 1010 at Day 54Plasma, and 1.00 × 1010 or Days liver, lung, 2 × 106 SC 3.33 × 109 35 (I×/week), eye, femur, CDC-EVs and 3.33 × 109 at colon Days 43, 47 and 50 (2×/week) - Every day for the study period, each animal was weighed, and its survival was recorded in order to assess possible differences among treatment groups and as an indication for GVHD severity and/or possible toxicity resulting from the treatments. Any animal losing >30% of their starting weight was euthanized.
- A clinical score for GVHD was obtained twice weekly for the entire study duration as assessed by a standard scoring system as detailed in Table 4, wherein the overall GVHD score was based on 5 criteria: percentage of weight change, posture (hunching) as exemplified in
FIGS. 2A-C , activity, fur texture as exemplified inFIGS. 3 A-C, and skin integrity as exemplified inFIGS. 4A-C , with the maximum index=10. -
TABLE 4 Criteria Grade 0 Grade 1Grade 2Weight loss <10% >10%, <25% >25% Posture Normal Hunching noted only Severe gait, impaired at rest movement Activity Normal Mild to moderately Stationary until decreased stimulated Fur texture Normal Mild to moderate Severe ruffling ruffling and/or poor grooming Skin Normal Scaling of paws Obvious areas of integrity and/or tail denuded skin - All animals were followed for at least 54 days. At the end of the study, all surviving animals were sacrificed by an overdose of CO2 and organs detailed in Table 4 were collected. Upon sacrifice, blood was collected by retro-orbital bleed into K2EDTA tubes. The blood was centrifuged and the plasma collected, flash frozen, and stored at −80° C. for further downstream analyses. Upon sacrifice, the liver was excised and the caudate lobe placed directly in formalin for 24 hours prior to transfer to 70% ethanol for long term storage. Upon sacrifice, the lungs and heart were removed en bloc, and the lungs were perfused with formalin through the heart right ventricle. The left (non-lobular) lung was removed and placed directly in formalin for 24 hours prior to transfer to 70% ethanol for long term storage.
- A) Statistical Analyses
- Parametric data (weight change, engraftment) were evaluated using one-way ANOVA with Holm-Sidak's multiple comparison test to compare all groups to the vehicle control group. Non-parametric data (GVHD scores) were analyzed with Kruskal-Wallis with Dunn's post-hoc test. All statistical analyses were performed using GraphPad Prism 6.01 Software (La Jolla, CA). Statistical significance was achieved when p<0.05.
- B) GVHD Score
- As assessed using the multi-parameter GVHD scoring systems shown in Table 4 and as shown in
FIG. 7A , intravenous injection of splenocytes and bone marrow cells induced GVHD in all animals. As shown inFIG. 7A , decreases in the overall GVHD score were observed in both groups dosed with CDC-EVs, and individual GVHD parameters (posture, activity, fur texture, skin integrity) are summarized inFIGS. 8A-D . - When an animal was forced to be euthanized because it had lost too much weight (>30% per IACUC protocol), the last observation was carried forward into subsequent data points to include the data for the dead animal.
- Referring to
FIG. 7B , the AUC was calculated to enable effective comparison of the groups by statistical test. - C) Body Weight Change
- As shown in
FIG. 6A , intravenous injection of splenocytes and bone marrow cells induced weight loss in all animals, and variable gains and losses were observed through the conclusion of the study. Following the initiation of dosing onDay 21, all animals continued to exhibit weight loss, peaking at around Day 33 followed by a partial recovery up until aroundDay 40. Animals dosed with either low dose or high dose of CDC-EVs continued to experience a general gain in weight up until the conclusion of the study onDay 54, whereas animals treated with the vehicle alone continued to lose weight. Indeed, the vehicle-treated animals had lost so much weight toward the end of the study that many of them were expected to die. - When an animal was forced to be euthanized because it had lost too much weight (>30% per IACUC protocol), the last observation was carried forward into subsequent data points to include the data for the dead animal.
- Referring to
FIG. 6B , the AUC was calculated to enable effective comparison of the groups by statistical test. - D) Survival
- As shown in
FIG. 9 , survival was tracked for all animals for the duration of the study and the percent survival was plotted, wherein treatment with both low dose and high dose CDC-EVs appeared to have beneficial effects on survival. - E) Bloody Stool & Diarrhea Incidence
- The incidence of bloody stool and diarrhea was tracked for the entire duration of the study. There was no incidence of bloody stool at any point during the study (data not shown). As shown in
FIGS. 10A-B , treatment with high dose CDC-EVs appeared to decrease the incidence of diarrhea, although no dramatic effect on diarrhea incidence was observed as a result of treatment with CDC-EVs. - F) Eye Inflammation
- Immediately prior to sacrifice at
Day 54, eye inflammation was assessed and scored, wherein a drop of 1% sodium fluorescein was applied to each eye, then the eye was rinsed off with saline, and viewed the fluorescence of the cornea with cobalt blue light under magnification. A masked/blinded observer assigned a score of 0 through 4 to each eye of each animal based on the degree of corneal fluorescein staining seen in the eye as follows: 0=no staining; 0.5=trace punctate staining: 1=punctate staining; 2=up to 25% staining of the corneal surface area; 3=up to 50% staining of the corneal surface area; 4=>50% corneal surface staining. The scores for each eye were averaged to achieve an “eye score” for each group.FIGS. 11 A-C show that while there was a trend toward lower eye score (therefore less corneal staining, a sign that there is reduced eye inflammation) in the CDC-EV-treated groups, with the high dose-treated animals performing even better. - 14 mouse colon samples and 14 mouse eyes from the animals of Groups 1-3 as described in Table 3 were processed routinely for histopathologic examination. One slide per block was sectioned and stained with hematoxylin and eosin (H&E) or microscopic analysis of tissue structure and inflammatory infiltrate. Glass slides were evaluated using light microscopy by a board-certified veterinary pathologist; colons were qualitatively evaluated and scored for inflammation, edema, mucosal erosion, and goblet cell depletion according to the histopathologic criteria listed in Tables 5-8. Each of the longitudinal sections on a given slide was scored. The mean score was calculated and reported for each parameter. Additionally, the mean sum score was calculated as the sum of inflammation, edema, mucosal necrosis, and goblet cell depletion.
-
TABLE 5 Inflammation Score Description 0 None present 1 Minimal change: Focal aggregate of a few cells of minimal diffuse inflammation 2 Mild change: Larger focal aggregates, multifocal small aggregates, or diffuse mild inflammation 3 Moderate change: Multifocal aggregates sometimes coalescing with one another or moderate diffuse change 4 Severe change: Marked diffuse inflammation -
TABLE 6 Edema Score Description 0 None present 1 Minimal change: Focal edema or minimal diffuse edema 2 Mild change: Larger focal areas of edema or diffuse mild edema 3 Moderate change: Multifocal areas of edema coalescing with one another or moderate diffuse edema 4 Severe change: Marked diffuse edema -
TABLE 7 Mucosal Necrosis/ Epithelial Damage Score Description 0 None present 1 Minimal change: Focal epithelial necrosis 2 Mild change: Larger focal areas of necrosis or multifocal areas of necrosis 3 Moderate change: Multifocal necrosis coalescing into larger areas 4 Severe change: Areas of erosion through the mucosa to the submucosa -
TABLE 8 Goblet Cell Depletion Score Description 0 None present 1 Minimal change: Focal goblet cell loss in one or a few colonic glands 2 Mild change: Larger focal areas of goblet cell loss, or multifocal goblet cell loss in several glands 3 Moderate change: Multifocal to regionally extensive goblet cell loss 4 Severe change: Marked diffuse goblet cell loss - Scores for each feature were summed to obtain a sum colitis score (range 0-16). Colonic histologic lesions not addressed in this grading scheme and lesions in eye sections were scored semi-quantitatively 0-5, where 0=not present, 1=minimal, 2=mild, 3=moderate, 4=marked, 5=severe. See, e.g., Crissman et al, “Best Practices Guideline: Toxicologic Pathology,” Toxicol Pathol, 32: 126-31 (2004).
- A) Colon
- Expected histologic lesions of GVHD colitis in mice included primarily mononuclear inflammation in the colonic mucosa; expansion of the submucosa and lymphatic vessels by edema; epithelial damage or mucosal necrosis, with or without erosion and infiltration of neutrophils; and depletion of goblet cells. See, e.g., Eigenbrodt et al, “Histologic Similarity of Murine Colonic Graft-versus-host Disease (GVHD) to Human Colonic GVHD and Inflammatory Bowel Disease,” Am J Pathol, 137: 1065-76 (1990). Additional expected lesions included lymphocytic satellitosis, the infiltration of lymphocytes into the colonic gland with epithelial cell apoptosis; epithelial hyperplasia, characterized by gland elongation, basophilia and increased mitotic figures; and mesenteric adipose necrosis with subacute inflammation, the infiltration of neutrophils, macrophages and fewer lymphocytes and plasma cells into the mesentery adjacent the colon.
- As shown in
FIGS. 12-13 , decreases in mucosal necrosis and goblet cell depletion scores in the test article-low dose group (Group 2) translated into a reduction in sum score compared to the untreated group (Group 1). - B) Eye
- Expected histologic lesions in eyes from mice with GVHD included lymphocytic satellitosis, characterized by infiltration of low numbers of lymphocytes into the corneal epithelium, with concurrent epithelial cell vacuolization and/or apoptosis; corneal epithelial necrosis with progression to ulceration was present in one sample. See, e.g., Perez et al, “Limbus Damage in Ocular Graft-versus-Host-Disease,” Biol Blood Marrow Transplant, 17: 270-273 (2011). Corneal subacute inflammation was characterized by infiltration of neutrophils, lymphocytes or histiocytes into the corneal stroma and/or epithelium, accompanied by stromal edema or occasional foci of stromal necrosis. Neovascularization was characterized by ingrowth of blood vessels into the corneal stroma. Subacute inflammation was also observed in the limbus, conjunctiva (when present) and the anterior uveal tract, including the iris or anterior chamber. Mineralization was visible in the corneal stroma or in the immediate sub-basilar zone of the corneal epithelium (subepithelial). Lens fiber degeneration (cataract formation), characterized by posterior migration and disorganization of the lens epithelium and bladder cell formation, was observed as well.
- As shown in
FIG. 15 , lymphocytic satellitosis, corneal and anterior uveal subacute inflammation and neovascularization scores were most severe in Group 1 (untreated); with lower scores or complete absence of these lesions in the test article-treated animals (Groups 2 and 3). - The purpose of this study was to determine the immunological activity of CDC-EVs linked to T cells regulation.
- For
FIG. 16 , the expression of exosome informative markers was analyzed by CDC-EVs using Western blotting. CDC-EVs (20 μl=10 μg) were lysed using RIP A buffer and loaded to 10% SDS-Page gels then transferred to nitrocellulose membrane. Membranes were blocked with 5% BSA then hybridized with specific antibodies against HSP70, CD81, CD63, ALIX, HLA II and p-actin. CDCs and dendritic cells (DC) lysates as well as exosome-free supernatant (SN) were used as controls. CDC-EVs expressed expected exosome markers CD81, CD63 and ALIX while SN was completely negative. - CDC-EVs were next analyzed for the surface expression of immune relevant markers. CDC-EVs (30 μl=15 μg) have been coupled to 5 μl Latex beads (4 μπι). CDC-EVs/beads were treated successively with 100 mM glycine and 2% BSA buffers in order to block any eventual non-specific binding of these EVs eads with antibodies or with beads. After washing, EVs/beads were stained with specific antibodies against relevant immune molecules acquired on Canto II BD Facs and analyzed by FlowJo software. Beads incubated with the same amount of respective antibodies were used as a control.
- Compared to beads-antibody control, CDC-EVs expressed HLA class I molecules and CD86, but were negative for HLA II and CD80 molecules. CDC-EVs seem to express the co-stimulatory PD-L1 molecule but not the ICOS-L. NK activating receptor ligands were remarkably expressed on the CDC-EVs. For
FIG. 17 , significant expression of both EVs markers CD81 and CD63 was detected. - Monocytes were isolated from blood samples obtained from two different healthy donors. Isolated-monocytes were then stimulated for 6 days with a combination of GM-CSF (20 ng/ml) and IL4 (20 ng/ml) to allow their differentiation to DC. Differentiation of monocytes with GM-CSF+IL4 generates immature DC (iDC) marked by moderate expression of HLA II, CD80, and CD86 molecules, absence of CD 16 (marker of monocytes/macrophages), and low expression of TLR-2. These monocyte-derived iDC were then incubated for an overnight with HLA-mismatched CDC-EVs.
- iDC cultured with EVs displayed features of mature DC (mDC); they up-regulated their HLA II, CD80 and CD86 molecules, which is recognized as mDC properties, as shown in
FIG. 28 . Then 1×104 of iDCs or iDCs that were in contact with EVs (iDC-EVs) were co-cultured with autologous T cells (1×105) in U-bottom 96 wells plates for another 6 days. Autologous T cells co-cultured with iDC or iDC-EVs where analyzed for their expression of CD69 and HLA-DR, and for their proliferation. Although the response of T cells from two different donors was variable, as a whole iDC-EV were more potent in activating and inducing the proliferation of T cells than iDCs alone, as shown inFIG. 29 . - Compared to direct CDC-EV-induced T cells proliferation, the magnitude of indirect CDC-EV-induced T cells proliferation is fairly higher.
- The capacity of CDC-EVs to stimulate T cells when presented by mature DC (mDC) was evaluated. Given that mDC have very low phagocytic activity and to insure appropriate uptake of EVs and based on previous experience of phagocytizing apoptotic bodies, the maturation of DC was induced by treating iDC and iDC-EVs for an overnight with IFNγ (500 IU/ml), which is a recognized inducer of DC maturation. Compared to iDC, these mDC showed higher expression of HLA II, CD80 and CD86, and higher expression of TLR-2, which are the know features of mDC. The presence of CDC-EVs during iDC maturation to mDC further up-regulated HLA II, CD86, CD80, and TLR-2 molecules, as shown in
FIG. 30 . - mDC or mDC-EVs were then co-cultured with autologous T cells (1×105) in U-bottom 96-wells plates or 6 days and their activation (expression of CD69 and HLA-DR) and proliferation was analyzed.
- Again, the responses from two donors, were variable but as a whole mDC-EVs were more potent in activating and inducing the proliferation of T cells than mDCs alone. Compared to iDC-EVs-induced response, mDC-EV-induced T cell activation and proliferation for the same donor was higher.
- The ensemble of our results in regard of T cells activation and proliferation suggest that CDC-EVs can activate and induce the proliferation of T cells mainly through the indirect pathway without rolling out the direct pathway since we did observe weak direct activation.
- The ability of T cells for CDC-EVs uptake was evaluated in vitro. Human CDC-EVs were fluorescently labeled using the membrane dye DiD and were added to Jurkat T cells (Jurkat, Clone E6-; ATTC® TIN-152™). Uptake was measured by
flow cytometry 1 hour, 4 hours, or overnight after addition of EVs. Jurkat T cells tested positive for DmiD fluorescence at the different times tested, indicating that they uptake CDC-EVs (FIG. 18 ). - The capacity of CDC-EVs to modulate an ongoing immune response in an allogeneic setting was then investigated. To this end, HLA-mismatched unfractionated CFSE-labeled PBMC (1×105) were stimulated with PHA (1 μg/ml) in the absence or presence of various doses of CDC-EVs as shown in
FIG. 19 (upper panel) in U-bottom 96 well plates and allogeneic T cells proliferation was evaluated by monitoring CFSE. CDC-EVs were able to down regulate PHA-induced CD4+ and CD8+ T cell proliferation. CDC-EVs-induced down regulation of T cells proliferation was dose dependent, and at the highest used dose (20×109 particles) CDC-EVs were more potent in down regulating ongoing response than their parental cells, as shown inFIG. 19 . - CDC-EV-induced immune modulation is likely through direct effects since similar results were obtained when purified CD3+ T cells were used instead of PBMC within the same experimental settings. Indeed, CDC-EVs were able to down regulate PHA-induced expression of CDC69 and/or HLA-DR on T cells obtained from 2 different donors, as shown in
FIG. 20 . - For
FIG. 21 , down-modulation of T cells activation markers by CDC-EVs resulted in a pronounced down regulation of PHA-induced CD4+ and CD8+ T cell proliferation. - For
FIG. 22 , despite inter-donor variability and within the limit of results obtained with two donors only, CDC-EVs are potent immune modulators. - These studies of capacity of CDC-EVs to induce immune-modulation demonstrated that they are potent immune-modulators.
Claims (20)
1. A method of modulating T cells, the method comprising contacting T cells with an effective amount of extracellular vesicles derived from cardiosphere-derived cells (CDCs).
2. The method of claim 1 , wherein proliferation of said contacted T cells is down regulated.
3. The method of claim 1 , wherein expression of CDC69 is down regulated in said contacted T cells.
4. The method of claim 1 , wherein expression of HLA-DR is down regulated in said contacted T cells.
5. The method of claim 1 , wherein expression of CDC69 and expression of HLA-DR are down regulated in said contacted T cells.
6. The method of claim 1 , wherein the T cells comprise CD3+ T cells.
7. The method of claim 1 , wherein the T cells comprise CD4+ or CD8+ T cells.
8. The method of claim 1 , wherein the extracellular vesicles express HLA class I molecules and do not express HLA II molecules.
9. The method of claim 1 , wherein the extracellular vesicles express CD86 and do not express CD80.
10. The method of claim 1 , wherein the extracellular vesicles express HLA class I and CD86 molecules and do not express HLA II and CD80 molecules.
11. The method of claim 1 , wherein the extracellular vesicles express PD-LI and do not express ICOS-L.
12. The method of claim 1 , wherein the extracellular vesicles express NK activating receptor ligands.
13. The method of claim 1 , wherein the extracellular vesicles express NK activating receptor ligands, PD-L1, CD86, and HLA class I molecules.
14. The method of claim 13 , wherein the extracellular vesicles do not express CD80, ICOS-L, and HLA II molecules.
15. The method of claim 1 , wherein the effective amount of the extracellular vesicles is 5×109 to 20×109 extracellular vesicle particles.
16. The method of claim 1 , wherein the T cells are in vivo and said contacting comprises administering said effective amount of extracellular vesicles to a subject.
17. The method of claim 16 , wherein the subject had received hematopoietic stem cell transplant (HSCT).
18. The method of claim 17 , wherein said effective amount of extracellular vesicles is administered one or more times after the subject had undergone HSCT.
19. The method according to claim 17 , wherein said effective amount of extracellular vesicles is administered 1, 2, 3, 4, 5, 6, 7, or 8 weeks after HSCT.
20. The method according to claim 17 , wherein said effective amount of extracellular vesicles is administered in multiple administrations made 7 days apart between successive administrations.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/983,797 US20230330154A1 (en) | 2017-05-05 | 2022-11-09 | Methods of treating systemic graft- versus-host disease with extracellular vesicles |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762502474P | 2017-05-05 | 2017-05-05 | |
US201762506880P | 2017-05-16 | 2017-05-16 | |
PCT/US2018/031257 WO2018204889A1 (en) | 2017-05-05 | 2018-05-04 | Methods of treating systemic graft-versus-host disease with extracellular vesicles |
US201916610859A | 2019-11-04 | 2019-11-04 | |
US17/983,797 US20230330154A1 (en) | 2017-05-05 | 2022-11-09 | Methods of treating systemic graft- versus-host disease with extracellular vesicles |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2018/031257 Continuation WO2018204889A1 (en) | 2017-05-05 | 2018-05-04 | Methods of treating systemic graft-versus-host disease with extracellular vesicles |
US16/610,859 Continuation US11529376B2 (en) | 2017-05-05 | 2018-05-04 | Methods of treating systemic graft-versus-host disease with extracellular vesicles |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230330154A1 true US20230330154A1 (en) | 2023-10-19 |
Family
ID=64016763
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/610,859 Active 2038-10-04 US11529376B2 (en) | 2017-05-05 | 2018-05-04 | Methods of treating systemic graft-versus-host disease with extracellular vesicles |
US17/983,797 Abandoned US20230330154A1 (en) | 2017-05-05 | 2022-11-09 | Methods of treating systemic graft- versus-host disease with extracellular vesicles |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/610,859 Active 2038-10-04 US11529376B2 (en) | 2017-05-05 | 2018-05-04 | Methods of treating systemic graft-versus-host disease with extracellular vesicles |
Country Status (4)
Country | Link |
---|---|
US (2) | US11529376B2 (en) |
EP (1) | EP3600151A4 (en) |
JP (1) | JP7360704B2 (en) |
WO (1) | WO2018204889A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3600151A4 (en) * | 2017-05-05 | 2021-01-13 | Capricor, Inc. | METHOD OF TREATMENT OF SYSTEMIC TRANSPLANT REJECTION WITH EXTRACELLULAR VESICLES |
CN113209133B (en) * | 2020-01-20 | 2023-05-23 | 医微细胞生物技术(广州)有限公司 | Application of vesicle in preparation of medicine for treating or preventing liver diseases |
KR20220139926A (en) | 2020-02-05 | 2022-10-17 | 다이아뎀 바이오쎄라퓨틱스 인크 | artificial synapse |
WO2021187911A1 (en) * | 2020-03-18 | 2021-09-23 | 가톨릭대학교 산학협력단 | Cord blood plasma-derived exosome or mimetic thereof and pharmaceutical use thereof |
CN118685365B (en) * | 2024-08-23 | 2024-11-15 | 昆明医科大学附属口腔医院(云南省口腔医院) | Construction and application of miR-423-5p high-abundance engineering vesicle |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11529376B2 (en) * | 2017-05-05 | 2022-12-20 | Capricor, Inc. | Methods of treating systemic graft-versus-host disease with extracellular vesicles |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2691296T3 (en) * | 2012-04-03 | 2018-11-26 | Reneuron Limited | Stem cell microparticles |
JP6433896B2 (en) * | 2012-08-13 | 2018-12-05 | シーダーズ−サイナイ・メディカル・センターCedars−Sinai Medical Center | Exosomes and microribonucleic acids for tissue regeneration |
EP3193890A4 (en) * | 2014-09-15 | 2018-03-14 | Agency For Science, Technology And Research | Methods of treating graft versus host disease (gvhd) or epidermolysis bullosa (eb) with exosomes |
US11260076B2 (en) * | 2014-10-27 | 2022-03-01 | University Of Central Florida Research Foundation, Inc | Methods and compositions for natural killer cells |
-
2018
- 2018-05-04 EP EP18795151.2A patent/EP3600151A4/en not_active Withdrawn
- 2018-05-04 WO PCT/US2018/031257 patent/WO2018204889A1/en unknown
- 2018-05-04 JP JP2019558492A patent/JP7360704B2/en active Active
- 2018-05-04 US US16/610,859 patent/US11529376B2/en active Active
-
2022
- 2022-11-09 US US17/983,797 patent/US20230330154A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11529376B2 (en) * | 2017-05-05 | 2022-12-20 | Capricor, Inc. | Methods of treating systemic graft-versus-host disease with extracellular vesicles |
Non-Patent Citations (1)
Title |
---|
Wang et al. ("Extracellular Vesicles Released from Human Umbilical Cord-Derived Mesenchymal Stromal Cells Prevent Life-Threatening Acute Graft-Versus-Host Disease in a Mouse Model of Allogeneic Hematopoietic Stem Cell Transplantation", Stem Cells and Development, Volume 25, Number 24, 2016, pages (Year: 2016) * |
Also Published As
Publication number | Publication date |
---|---|
US11529376B2 (en) | 2022-12-20 |
EP3600151A1 (en) | 2020-02-05 |
JP7360704B2 (en) | 2023-10-13 |
EP3600151A4 (en) | 2021-01-13 |
JP2020518564A (en) | 2020-06-25 |
US20200054686A1 (en) | 2020-02-20 |
WO2018204889A1 (en) | 2018-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230330154A1 (en) | Methods of treating systemic graft- versus-host disease with extracellular vesicles | |
AU2017218143B2 (en) | Adipose tissue derived mesenchymal stromal cell conditioned media and methods of making and using the same | |
US20240075074A1 (en) | Use of umbilical cord blood derived exosomes for tissue repair | |
JP7249693B2 (en) | Compositions for skin regeneration and wound healing containing induced exosomes | |
JP7022994B2 (en) | How to treat eye inflammation and chemical damage to the eye with extracellular vesicles | |
EP1888123B1 (en) | A cellular therapy for ocular degeneration | |
US20210113625A1 (en) | Extracellular vesicles derived from mesenchymal stem cells | |
KR101480362B1 (en) | Pharmaceutical composition comprising stem cells treated with NOD2 agonist or culture thereof for prevention and treatment of immune diseases and inflammatory diseases | |
US20170304368A1 (en) | Polarization of macrophages to a healing phenotype by cardiosphere-derived cells and by the exosomes secreted by such cells | |
AU2018335788B2 (en) | Methods and compositions for the treatment of epidermolysis bullosa | |
KR20220024060A (en) | Exosomes for disease treatment | |
JP7640053B2 (en) | Composition for preventing or treating diabetic skin disease comprising exosomes derived from thrombin-treated stem cells | |
JP2020023502A (en) | Methods and compositions for stimulation of cell proliferation, and provision of biologically active mixtures of fgf2 isoforms | |
KR20190003399A (en) | A composition comprising an exosome derived from stem cell as an active ingredient and its application for improving skin fibrosis | |
Ou et al. | The role of cells and their derivatives in otorhinolaryngologic diseases treatment | |
CN119497622A (en) | Isolation, enrichment, and expansion of human rod progenitor cells and extracellular vesicles derived therefrom |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |